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A series of novel RGD mimetics containing phthalimidine fragment was designed and synthesized. Their
antiaggregative activity determined by Born’s method was shown to be due to inhibition of ﬁbrinogen
binding to aIIbb3. Molecular docking of RGD mimetics to aIIbb3 receptor showed the key interactions in
this complex, and also some correlations have been observed between values of biological activity and
docking scores. The single crystal X-ray data were obtained for ﬁve mimetics.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction aggregation regardless of the activation pathway.3,4 Inhibitors ofThrombosis is the most important pathological process under-
lying many cardiovascular diseases, which are responsible for ele-
vated mortality worldwide.1 The use of ADP and thromboxane
inhibition does not preclude the formation of thrombus, because
platelets can still be activated by other mechanisms. It gave a stim-
ulus to the development of an entirely separate class of antiplatelet
drugs - ﬁbrinogen receptor (integrin aIIbb3) antagonists. During the
platelet activation process, the surface of the platelet transforms its
shape to expose the ﬁbrinogen receptors. These receptors bind to
ﬁbrinogen and Von Willebrand factor, resulting in clot formation
and clot adherence, respectively.2 Binding of ﬁbrinogen to aIIbb3
on platelets is responsible for securing aggregated platelets to
one another. Thus, blocking these receptors prevents plateletaIIbb3 have proven useful in reducing the risk of periprocedural
MI and urgent target vessel revascularization during catheteriza-
tion and have claimed a place in therapy for these indications.5
There exist three different aIIbb3 inhibitors approved for use: abcix-
imab (Eli Lilly & Company, Indianapolis, Indiana), eptiﬁbatide
(Schering-Plough, Kenilworth, New Jersey), and tiroﬁban (Medi-
cure, Winnipeg, Canada).6 However, the current agents have sev-
eral limitations, including the need for intravenous infusion and,
most important, the induction of thrombocytopenia in some pa-
tients.7 These limitations of above mentioned drugs give evidence
of need in new aIIbb3 inhibitors.
Although, more frequently the design of aIIbb3 antagonists is
based on the mimicking of Arg–Gly–Asp (RGD) sequence, alterna-
tive approach represents the use of dodecapeptide sequence.8,9 The
main binding sites of RGD sequence are d-guanidine of arginine
and b-carboxylic group of aspartyl, and for the dodecapeptide se-
quence - lysine amino group and aspartyl carboxylic group, corre-
spondingly. Similarity of these two approaches is evident.
In our recent publication, the use of phthalimidine scaffolds for
designing potent integrin aIIbb3 antagonists has been demon-
Figure 1. View of 5b. ORTEP diagram with the numbering scheme. The thermal
A. A. Krysko et al. / Bioorg. Med. Chem. 21 (2013) 4646–4661 4647strated.10 Herein, we describe the optimization of the novel Arg
surrogates for obtaining RGD mimetics active inhibitors.
This article describes the synthesis of new RGD mimetics con-
taining phthalimidine (2,3-dihydroisoindol-1-one) fragment and
study of their antiaggregative properties. We also discuss the pos-
sibility to use the residues of 4-piperidineacetic, 4-piperidine-4-yl-
butyric, 4-piperidine-4-yl-benzoic, 4-piperazine-1-yl-benzoic, 1,2,
3,4-tetrahydroisoquinoline-7-carboxylic, and 3-piperazine-1-yl-
benzoic acids as Arg surrogates for RGD mimetics design.ellipsoids are of 50% probability level, with hydrogens as spheres of arbitrary
diameter.
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Scheme 2. Synthesis of the acids 11 and 14. Reagents: (a) HCl⁄NH(CH2CH2Cl)2,
K2CO3, BuOH, reﬂux, 177 h; (b) Boc2O, room temperature, overnight; (c) NaOH,
H2O 40 C, 6 h; (d) HCl, H2O; (e) (COCl)2, AlCl3; (f) NaOH, H2O.2. Results and discussion
2.1. Synthesis
Description of the synthesis of 6-amino-2,3-dihydroisoindolin-
1-one building blocks 5a–d was given in a previous report
(Scheme 1). The key step was the formation of the 6-amino-2,3-
dihydroisoindolin-1-one building blocks 5a–d by reduction of
phthalimides 1a–d using zinc amalgam. As a result of nitration of
the compounds 2a–d, there were obtained nitro-derivatives 3a–d
followed by their reduction by H2/Pd(C). Regioselectivity of nitra-
tion reaction is expected. The X-ray analysis data obtained for
the compound 5b is a conﬁrmation.
The view of molecular structure of 5b is shown in Figure 1. The
molecule has a rather ﬂat skeleton as evidenced by the dihedral an-
gle of 8.8 between the planes of almost coplanar nonhydrogen
atoms of methylpropionate chain and phthalimide core. The geo-
metric parameters of planar aminophthalimide core are in line
with the related 3-(1-oxo-1,3-dihydroisoindol-2-yl)propionic
acid,11 but these molecules differ by the molecular shape as far
as the latter one has an angular conformation.
Homologation of Boc protected piperidine-4-carboxylic acid
gave the 1-Boc-4-piperidineacetic acid (6), by a similar method re-
ported in the literature.12 Initial Boc derivatives of the 4-piperi-
dine-4-yl-butyric (7)13 and 4-piperidine-4-yl-benzoic (8)14 acids
have been synthesized using previously published methods. Iso-
meric methyl esters of the 4-piperazine-4-yl-benzoic (9a)15 and
3-piperazine-4-yl-benzoic (9b) acids were made using methyl es-
ters of aminobenzoic acids and bis-(2-chloroethyl)amine. Boc-pro-
tection of the compounds 9a and 9b with Boc2O resulted in the
methyl esters 10a and 10b, respectively. Subsequent saponiﬁcation
of ester groups of compounds 10a and 10b yielded the target acids
11a,b (Scheme 2).
Precursor compound 14 was prepared in three steps in contrast
to our previously published route for four-steps synthesis.16 Acyl-
ation of 2-acetyl-1,2,3,4-tetrahydroisoquinoline (12) with oxalyl
chloride at the presence of aluminum chloride gave 1-acetyl-
1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid (13). FurtherN
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Scheme 1. Synthesis of aminophthalimidines. Reagents: (a) Zn (Hg), HCl, reﬂux, 4 h; (b)
temperature, 7 h.removal of the acetyl group and reaction with Boc2O resulted in
the acid 14 (Scheme 2). The structure of compound 14 has been
conﬁrmed by data of X-ray analysis (Fig. 2).
The molecular structure 15 is shown in Figure 2. The molecule
has an angular shape with the aza-cycle of the 1,2,3,4-tetrahydro-
isoquinoline core being in a half-chair conformation with the N1
atom deviating at 0.574(3) Å from the mean plane of cyclic C-
atoms, the rms deviation of ﬁtted carbon atoms being 0.056 Å.
Condensation of acids 6–8, 11a,b and 14 with amines 5a–d has
been conducted using the HBTU or HATU (Scheme 3). Subsequent
saponiﬁcation of ester groups of the compounds 15a–u andR
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HNO3, H2SO4, 5 C, 6 h; (c) MeOH (H2SO4), reﬂux, 3 h; (d) H2/Pd (C), MeOH, room
Figure 2. View of 15. ORTEP diagram with the numbering scheme. The thermal
ellipsoids are of 50% probability level, with hydrogens as spheres of arbitrary
diameter.
4648 A. A. Krysko et al. / Bioorg. Med. Chem. 21 (2013) 4646–4661elimination of Boc-protective groups yielded the target mimetics
17a–u. Mimetics 17l–q were obtained only as racemic mixtures
in order to reveal potent compounds and to determinate general
characteristics of structure–activity relationships.
2.2. X-ray structure
Fortunately, single crystals of target compounds were grown
from water, and X-ray data were obtained for ﬁve mimetics,
17c,h,i,j,t. They were ﬁxed in the solid crystalline state as either tri-
ﬂuoroacetate or chloride salt with the compositions 17c,h and
17i,j,tH2O. After 2 h of boiling of aqueous solutions of compounds
17c and 17h and then their cooling to room temperature, single
crystals were grown. They were identiﬁed as the hydrates of zwit-
terionic forms, 17c-TfaOH5H2O and 17h-TfaOH2H2O. The ORTEP
drawings for the formula units are shown in Figure 3. All the
mimetics molecules bear three planar fragments, the benzoyl ring,
the 1-oxo-1,3-dihydroisoindolyl core with the equivalent bond
lengths being similar within themselves, in the parent 5b and in
the closely related 3-(1-oxo-1,3-dihydroizoindol-2-yl)propionic
acid,11 and the amide bridge between these moieties. The amide
bridge is always ﬁxed in the syn-conformation with regard to theN
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Scheme 3. Synthesis of RGD mimetics. Reagents: (a) NEt3, HBTU, 5a–d, room temperatu
CH2Cl2, HCl gas, 0 C, 1 h or CH2Cl2, TFA, 0 C, 2 h.phthalimidine core and anti-conformation with regard to the
benzoyl moieties as the torsion angles O2–C9–N2–C6 and C10–
C9–N2–C6 indicate falling in the ranges 0.6(8)–8.7(9) and
171.1(6)–179(1), respectively (Table 1). The molecules differ by
mutual orientations of the above-mentioned planar molecular
moieties, by the orientation of piperidine or piperazine fragment
with respect to the benzoyl moieties, and carboxylic tails with
respect to the indolyl core. Moreover, the different mutual arrange-
ment (cis- or trans-) of the amide and indolyl carbonyl oxygen
atoms O1 and O2 should be mentioned. The conformational ﬂexi-
bility and essential variation of cross-molecule distance between
the distal cyclic N and carboxylic O-atoms in the wide range
16.297–21.434 Å, Table 1, indicate the possibility to ﬁne tuning
substrate-receptor interactions.
2.3. In vitro biology
Functional activity was determined by measuring the inhibition
of ADP induced platelet aggregation in human platelet-rich plasma
(PRP) by Born’s method.17 Mode of action for some compounds was
subsequently revealed in vitro by measuring the ability of com-
pounds to inhibit the binding of ﬂuoresceinisothiocyanate-labeled
ﬁbrinogen (FITC-Fg)18 to aIIbb3 (in a suspension of human washed
platelets).19 Experimental data (Table 2) evidently show high afﬁn-
ities of the compounds 17 for aIIbb3. RGDS peptide and Tiroﬁban
were used as standard inhibitors.
We ﬁrst investigated the SAR of compounds 17a–e, containing a
fragment of (1-oxo-1,3-dihydroisoindol-2-yl)acetic acid. These
compounds showed low in vitro antiaggregative activity, except
for the leader of the group, mimetic 17d containing 4-piperazine-
4-yl-benzoyl, as Arg isostere. Homologation of C-terminal template
resulted in increased activity for ﬁve compounds 17f–j containing
the same surrogates of Arg. Here again was the leading mimetic
17i, containing a residue of 4-piperazine-4-yl-benzoic acid. Lead-
ing indicators of antiaggregative activity of compounds containing
4-piperazine-4-yl-benzoyl, forced us to test 3-piperazine-4-yl-ben-
zoyl derivative 17k. It was found that the compound 17k was ﬁve
times less active than its isomer 17i. Further increase of C-terminalO
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aggregative properties. Surprise for us was the value of IC50 for
compound 17r. Mimetic 17r was more active than the mimetic17b, these two compounds have the same number of atoms
between the N- and C-terminals. Finally, replacing C-terminal frag-
ment b-alanine with b-methyl-b-alanine led to compounds 17l–p.
Table 1
Main geometrical parameters for 17 entities in studied compounds
Compounds Geometric parameter
a/1 () b/2 () c/1 () d/2 () e/3 () f/4() gr (Å)
17c-TfaOH5H2O 2.5(3) 176.8(2) 84.87(5) 26.51(8) 7.48(6) 79.1(2) 16.466(2) 18.377(2)
17c 4.4(6) 174.3(3) 87.5(1) 23.7(2) 39.7(1) 59.7(3) 17.256(5) 18.718(5)
17h-TfaOH2H2O 1.7(4) 175.6(3) 70.53(9) 4.9(2) 45.1(1) 10.3(3) 18.913(3) 19.6857(3)
17h 3(3) 179(1) 61.1(7) 15.3(9) 65.3(4) 9.8(9) 18.05(3) 19.10(3)
17iH2O 2.2(4) 175.3(2) 56.06(8) 22.3(1) 17.3(1) 8.6(6) 16.297(4) 16.885(4)
17jH2O 0.6(8) 179.5(4) 3.8(3) 29.9(2) 30.9(2) 75.8(2) 16.803(7) 17.091(7)
17tH2O 8.7(9) 171.1(6) 80.2(2) 16.6(3) 15.8(3) 15.5(1) 20.235(7) 21.434(7)
a Torsion angle O2–C9–N2–C6.
b Torsion angle C10–C9–N2–C6.
c Dihedral angle between the average planes through the terminal piperydine/piperazine ring and phenyl ring, C10/C11/C12/C13/C14/C15.
d Dihedral angle between the average planes through the phenyl ring, C10/C11/C12/C13/C14/C15 and amide bridge, C10/C9/O2/N2/C6.
e Dihedral angle between the average planes through the amide bridge, C10/C9/O2/N2/C6 and phthalimidine core, C1 > C8/N1/O1.
f Dihedral angle between the average planes through the phthalimidine core, C1 > C6/N1/O1 and carboxylic group, deﬁned by C,O,O atoms.
g Cross-molecule distance between the cyclic N and carboxylic O-atoms.
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activity observed for mimetics containing b-methyl-b-alanine frag-
ment (17o and 17q) was lower than for unsubstituted ones (17i
and 17k). As for methylated/unmethylated pairs 17m/18g and
17n/17h, their antiaggregative activities were nearly equal. Posi-
tive effect of methyl group was observed only for compounds 17l
and 17p compared to their unsubstituted analogs 17f and 17j, cor-
respondingly. Compound 17p possessed the highest antiaggrega-
tive activity among all compounds synthesized in this study.2.4. Molecular docking
Molecular docking studies have been performed in order to
give a microscopic insight into experimentally observed struc-
ture–property relationship. FlexX tool from LeadIT package has
been used.20 The X-ray structure of complex of Tiroﬁban with
headpiece of aIIbb3 integrin (2VDM) has been taken from Protein
Data Bank.21 Structure of the pocket has been prepared and four
water molecules have been kept in the cavity: two water mole-
cules, coordinated with Mg2+ metal ion-dependent adhesive site
(MIDAS) of the aIIbb3 integrin, and two water molecules coordi-
nated with Asp232 residue of the aIIb-subunit. Investigated com-
pounds have been docked in the prepared pocket. Because the
interaction of ligands of aIIbb3 integrin with aAsp224 and MIDAS
are essential for compound binding and activity, only best poses
which follow these requirements have been taken for further
analysis.21
A reasonable correlation between afﬁnity for aIIbb3 and docking
score has been observed (RSpearman = 0.72, Fig. 4) for a small subset
of compounds for which the activity values were available. Antiag-
gregative activity poorly correlateswith docking score (RSpearman = 0.35).
However, exclusion of one outlier (compound 17u) signiﬁcantly
improves the correlation (RSpearman = 0.52, Fig. 4).
Discovered correlations suggest that docking score can be used
for elucidation of antiaggregative activity of the compounds. Thus,
higher antiaggregative potency of 17f–j compared to 17a–e could
be explained by the fact that the former form additional H-bonds
to OH-group of Tyr190 or to water molecules connected with
aAsp232, whereas the latter cannot form hydrogen bonds to OH-
group of aTyr190 due to the steric reasons (Fig. 5, compounds
17e and 17j).
Compounds 17s,t resulted from the increase of length of the
Asp-mimetic part of 17g,h, are too big compared to the cavity
and, therefore they do not interact efﬁciently with the protein res-
idues (Fig. 5, compounds 17h and 17t).The difference between
activity of the compounds 17b and 17r, which have the sametopological length between Asp- and Arg-mimetic parts, can be ex-
plained by different protein–ligand interaction patterns. The car-
boxylic acid group of 18r is buried deeper in the receptor pocket
and interacts with bAsn215 as well as with MIDAS, and carbonyl
group of 2,3-dihydroisoindol-1-one moiety forms H-bond with
OH-group of aTyr190. On the other hand, carboxylic acid group
of 17b interacts only with MIDAS, whereas carbonyl group of 4-
piperidin-4-yl-butanoyl forms H-bond with water molecules coor-
dinated to aAsp232 (Fig. 5, compounds 17b and 17r). Comparison
of the docking pose of 17i with that of 17d shows that 17i is char-
acterized by bent conformation whereas 18d adopts almost linear
form. Furthermore, 17i is characterized by higher docking score va-
lue compared to 17d (38.6 vs 36.4).3. Conclusion
This paper is devoted to rational design of the aIIbb3 integrin
antagonists. It has been demonstrated that RGD mimetics contain-
ing 2,3-dihydroisoindol-1-one can be efﬁﬁciently used as aIIbb3
antagonists and platelet aggregation inhibitors through appropri-
ate structural modulation. In particular, modiﬁcation of the Arg
surrogates represents an attractive way of optimizing aIIbb3
integrin ligands. It can be summarized that the most preferable
structural features for high antiaggregative activity are tetrahydro-
isoquinoline and b-methyl-b-alanine as Arg and Asp bioisosteres,
respectively. Combination of these fragments within the given
phthalimidine series leads to the best prospective inhibitor of
platelet aggregation. The most active compounds identiﬁed display
favorable biological properties which are promising for further
development of antithrombotics.4. Experiment
4.1. Chemistry
Melting points are uncorrected. 1H and 13C NMR spectra were
recorded on Bruker AVANCE-II-400 (at 400 MHz for proton), or
Bruker Avance DRX 500 (at 500 MHz for proton and 125 MHz for
carbon) spectrometers with chemical shifts in ppm with the inter-
nal TMS as a standard. Electron ionization (EI) and fast-atom bom-
bardment (FAB) mass spectra were recorded on a VG Analytical VG
70-70EQ instrument. FAB spectra were performed equipped with
an argon primary atom beam, and anm-nitrobenzyl alcohol matrix
was utilized. High-resolution mass spectra (HRMS) were recorded
under FAB conditions. The purity was measured by HPLC
Table 2
Biological properties of RGD mimetics 17, RGDS peptide and Tiroﬁban
Compounds HX Aa n R IC50, (PRP)a (lM) IC50, (FITC-Fg/aIIbb3)b (lM)
17a TFA ONH 0 H 51 ± 11.0 ––
17b TFA NH O 0 H 66.0 ± 9.0 ––
17c TFA
O
NH 0 H 24.0 ± 3.0 0.27 ± 0.06
17d TFA
O
NNH 0 H 3.3 ± 0.5 ––
17e HCl
O
NH 0 H 120.0 ± 20.0 1.2 ± 0.1
17f TFA ONH 1 H 7.4 ± 1.4 ––
17g TFA NH O 1 H 5.9 ± 0.6 0.0055 ± 0.009
17h TFA
O
NH 1 H 9.6 ± 1.9 0.0068 ± 0.0012
17i TFA
O
NNH 1 H 0.54 ± 0.06 ––
17j HCl
O
NH 1 H 1.1 ± 0.1 0.0065 ± 0.0005
17k TFA
O
N
NH
1 H 2.7 ± 0.5 ––
17l TFA ONH 1 CH3 2.7 ± 0.6 ––
17m HCl NH O 1 CH3 5.4 ± 1.0 0.35 ± 0.03
17n HCl
O
NH 1 CH3 6.2 ± 1.2 ––
17o HCl
O
NNH 1 CH3 3.74 ± 0.51 0.037 ± 0.08
17p HCl
O
NH 1 CH3 0.086 ± 0.007 0.0065 ± 0.0012
17q HCl
O
N
NH
1 CH3 62.0 ± 5.0 ––
17r TFA ONH 2 H 1.8 ± 0.3 ––
17s TFA NH O 2 H 51.0 ± 3.0 ––
17t TFA
O
NH 2 H 410.0 ± 60.0 ––
17u HCl
O
NH 2 H 330.0 ± 50.0 ––
RGDS 31.0 ± 2.0 13.0 ± 1.6
Tiroﬁban 0.032 ± 0.004 0.0024 ± 0.0004
a Concentration required to reduce ADP-induced human platelet aggregation response by 50%. The IC50 values are expressed as the average of at least three determinations.
The average error for the IC50 determinations was 15%.
b Concentration required to reduce binding of FITC-Fg to aIIbb3 on the suspension of washed human platelets by 50%. The IC50 values are expressed as the average of at least
three determinations. The average error for the IC50 determinations was 15%.
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two pumps LC-8A and Photo-diode Array detector SPD-M20A)
using a Hypersil GOLD 3 lm (4.6  150 mm) or Hypersil GOLD
aQ 3 lm (4.6  150 mm) column. The progress of reactions was
monitored by TLC (silica gel 60 F254, Merck).
The compound 11a was prepared from 4-aminobenzoic acid
methyl ester by the procedure. The method of synthesis of 11b
from 3-aminobenzoic acid methyl ester not signiﬁcantly differ
from the procedure for compound 11a. The acids 7, 8 and 14 have
been synthesized using previously published method.4.1.1. General procedure for a preparation of compound 2
24.5 g of mossy zinc was amalgamated with 1 g of metallic mer-
cury and 1 M HCl solution (100 ml) in water. The suspension was
shaken for 5 min, and then the aqueous layer was discarded. The
zinc was covered with 24.5 ml of concentrated HCl and to this
was added 0.0488 mol of compound 1. The mixture was heated
to boiling for 0.5 h. At this stage, it is necessary to keep the reaction
temperature under control (at rapid foaming, heating was termi-
nated and reaction mixture was shortly cooled externally). After
all the compound 1was dissolved the mixture was boiled under re-
17e 17j
17h 17t 
17d 17i 
17b
17r 
Figure 5. Docking poses and interactions of compounds 17b,d,e,h–j,r,t inside the aIIbb3 receptor cavity.
Figure 4. Plots of afﬁnity for aIIbb3 of 17c,e,g,h,j,m,o,p and antiaggregative activity of 17a–u against docking score.
4652 A. A. Krysko et al. / Bioorg. Med. Chem. 21 (2013) 4646–4661ﬂux for 4 h. The hot solution was decanted from undissolved zinc
and allowed to cool. A white crystalline solid precipitated
and was collected. Recrystallization from water to give pure com-
pound 2.4.1.1.1. (1-Oxo-1,3-dihydroisoindol-2-yl)acetic acid (2a). Mp =
177–179.5 C; 1H NMR d (500 MHz, d6-DMSO) 4.30 (s, 2H), 4.53
(s, 2H), 7.50–7.53 (m, 1H), 7.56–7.58 (m, 2H), 7.68 (d, J = 7.4 Hz,
1H), 12.93 (s, 1H); MS (EI) m/z: 191.
A. A. Krysko et al. / Bioorg. Med. Chem. 21 (2013) 4646–4661 46534.1.1.2. 3-(1-Oxo-1,3-dihydroisoindol-2-yl)propionic acid (2b).
Mp = 113–116 C; 1H NMR d (500 MHz, d6-DMSO) 2.62 (t,
J = 7.0 Hz, 2H), 3.74 (t, J = 7.0 Hz, 2H), 4.50 (s, 2H), 7.47–7.50
(m, 1H), 7.60 (d, J = 3.6 Hz, 2H), 7.68 (d, J = 7.3 Hz, 1H), 12.34
(br s, 1H); MS (EI) m/z: 205.
4.1.1.3. 3-(1-Oxo-1,3-dihydroisoindol-2-yl)butyric acid (2C).
Mp = 205.5–206 C; 1H NMR d (500 MHz, d6-DMSO) 1.28 (d,
J = 6.6 Hz, 3H), 2.64 (ddd, J = 31.4, 15.3, 7.3 Hz, 2H), 4.46 (dd,
J = 28.4, 17.6 Hz, 2H), 4.62 (dt, J = 13.9, 6.6 Hz, 1H), 7.47–7.50 (m,
1H), 7.60–7.61 (m, 2H), 7.67 (d, J = 7.6 Hz, 1H), 12.26 (br s, 1H); MS
(EI) m/z: 219.
4.1.1.4. 4-(1-Oxo-1,3-dihydroisoindol-2-yl)butyric acid (2d).
Mp = 125–127 C; 1H NMR d (400 MHz, d6-DMSO) 1.8 (dt,
J = 14.2, 7.2 Hz, 2H) 2.2 (t, J = 7.3 Hz, 2H) 3.5 (t, J = 7.0 Hz, 2H) 7.5
(m, J = 7.9, 7.9, 4.0 Hz, 1H) 7.6 (m, J = 3.9 Hz, 2H) 7.7 (d, J = 7.6 Hz,
1H) 12.1 (br s, 1H); MS (EI) m/z: 219.
4.1.2. General procedure for a preparation of compound 3
Compound 2 (0.0252 mol) was dissolved in concentrated H2SO4
(37.7 ml) at 0 C, and to this solution was added HNO3 (12.7 ml,
d = 1.5) at 10 C. The mixture was stirred for 6 h at 5 C. The
reaction mixture was poured onto crushed ice (200 g). A crystalline
solid precipitated and was collected. The ﬁltered product was
recrystallized from methanol.
4.1.2.2. (6-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)acetic acid (3a)
Mp = 222–223 C; 1H NMR d (400 MHz, DMSO-d6) 4.33 (s, 2H), 4.68
(s, 2H), 7.91 (d, J = 8.3 Hz, 1H), 8.37 (d, J = 2.1 Hz, 1H), 8.48 (dd,
J = 2.1 Hz, 8.3 Hz, 1H); MS (EI) m/z: 219.
4.1.2.3. 3-(6-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)propionic
acid (3b). Mp = 196.5–197 C; 1H NMR d (400 MHz, DMSO-d6)
2.65 (t, J = 7.0 Hz, 2H), 3.77 (t, J = 7.0 Hz, 2H), 4.67 (s, 2H), 7.90 (d,
J = 8.3 Hz, 1H), 8.33 (d, J = 2.1 Hz, 1H), 8.45 (dd, J = 2.1 Hz,
J = 8.3 Hz, 1H); MS (EI) m/z: 250.
4.1.2.4. 3-(6-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)butyric acid
(3C). Mp = 194–195 C; 1H NMR d (500 MHz, d6-DMSO) 1.31 (d,
J = 6.8 Hz, 3H), 2.67 (ddd, J = 36.9, 15.5, 7.3 Hz, 2H), 4.58–4.68 (m,
3H), 7.90 (d, J = 8.3 Hz, 2H), 8.33 (d, J = 1.7 Hz, 1H), 8.46 (dd, J = 8.3,
1.7 Hz, 1H), 12.31 (s, 1H); MS (EI) m/z: 264.
4.1.2.5. 4-(6-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)butyric acid
(3d). Mp = 153–155 C; 1H NMR d (500 MHz, d6-DMSO) d ppm
1.87 (dt, J = 13.8, 7.0 Hz, 2H) 2.28 (t, J = 7.0 Hz, 2H) 3.59 (t,
J = 7.0 Hz, 2H) 4.65 (s, 2H) 7.90 (d, J = 8.3 Hz, 1H) 8.34 (s, 1H)
8.46 (d, J = 8.0 Hz, 1H) 12.07 (s, 1H); MS (EI) m/z: 264.
4.1.3. General procedure for a preparation of compound 4
Compound 3 (0.0169 mol) was dissolved in methanol (50 ml),
and to this solution was added concentrated H2SO4 (0.5 ml). The
reaction solution was reﬂuxed for 3 h. The solvent was removed
via evaporation in vacuo, and the residue was triturated with
water. A solid precipitated and was collected. The ﬁltered product
was recrystallized from methanol.
4.1.3.1. (6-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)acetic acid methyl
ester (4a). Mp = 113–115 C; 1H NMR d (400MHz, d6-DMSO) 3.70
(s, 3H), 4.46 (s, 2H), 4.70 (s, 2H), 7.94 (d, J = 8.3 Hz, 1H), 8.39 (d,
J = 2.1 Hz, 1H), 8.50 (dd, J = 2.1 Hz, 8.3 Hz, 1H); MS (EI) m/z: 250.
4.1.3.2. 3-(6-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)propionic acid
methyl ester (4b). Mp = 150–152 C; 1H NMR d (400MHz, d6-
DMSO) 2.74 (t, J = 7.0 Hz, 2H), 3.62 (s, 3H), 3.80 (t, J = 7.0 Hz, 2H), 4.67(s, 2H), 7.90 (d, J = 8.3 Hz, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.46 (dd, J = 8.3,
2.0 Hz, 1H); MS (EI) m/z: 264.
4.1.3.3. 3-(6-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)butyric acid
methyl ester (4C). Mp = 125–126 C; 1H NMR d (500 MHz, d6-
DMSO) 1.32 (d, J = 6.8 Hz, 3H) 2.76 (ddd, J = 35.4, 15.2, 7.3 Hz, 2H)
3.57 (s, 3H) 4.59–4.67 (m, 3H) 7.91 (d, J = 8.3 Hz, 1H) 8.34 (s, 1H)
8.46 (dd, J = 8.3, 2.2 Hz, 1H); MS (EI) m/z: 278.
4.1.3.4. 4-(6-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)butyric acid
methyl ester (4d). Mp = 86–87 C; 1H NMR d (500 MHz, d6-
DMSO) 1.90 (dt, J = 13.8, 6.7 Hz, 2H), 2.37 (t, J = 7.0 Hz, 2H), 3.55 (s,
3H), 3.59 (t, J = 6.7 Hz, 2H), 4.65 (s, 2H), 7.90 (d, J = 8.3 Hz, 1H), 8.34
(s, 1H), 8.46 (d, J = 8.3 Hz, 1H); MS (EI) m/z: 278.
4.1.4. General procedure for a preparation of compound 5
The nitro compound 4 (0.015 mol) dissolved in methanol
(100 ml) was subjected to catalytic hydrogenation at room temper-
ature for 7 h in the presence of 3% palladium on carbon (1 g).
The ﬁltered solution was then evaporated in vacuo to give com-
pound 5.
4.1.4.1. (6-Amino-1-oxo-1,3-dihydroisoindol-2-yl)acetic acid
methyl ester (5a). Mp = 142–143 C; 1H NMR d (400 MHz, d6-
DMSO) 3.68 (s, 3H), 4.32 (s, 2H), 4.34 (s, 2H), 5.38 (s, 2H), 6.83 (dd,
J = 2.1 Hz, 8.1 Hz, 1H), 6.87 (d, J = 2.1 Hz, 1H), 7.23 (d, J = 8.1 Hz,
1H); MS (EI) m/z: 220.
4.1.4.2. 3-(6-Amino-1-oxo-1,3-dihydroisoindol-2-yl)propionic
acid methyl ester (5b). Mp = 147–148.5 C; 1H NMR d
(400 MHz, d6-DMSO) 2.66 (t, J = 7.1 Hz, 2H), 3.61 (s, 3H), 3.71 (t,
J = 7.1 Hz, 2H), 4.28 (s, 2H), 5.30 (s, 2H), 6.79 (dd, J = 2.1 Hz,
J = 8.0 Hz, 1H), 6.82 (d, J = 2.1 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H); MS
(EI) m/z: 234.4.1.4.3. 3-(6-Amino-1-oxo-1,3-dihydroisoindol-2-yl)butyric acid
methyl ester (5C). Mp = 86–86.5 C; 1H NMR d (500 MHz,
d6-DMSO) 1.25 (d, J = 6.8 Hz, 3H), 2.68 (ddd, J = 27.0, 15.1, 7.3 Hz,
2H), 3.56 (s, 3H), 4.23 (dd, J = 24.5, 16.4 Hz, 2H), 4.58 (dt, J = 13.9,
6.8 Hz, 1H), 5.30 (s, 2H), 6.79 (dd, J = 8.1, 1.5 Hz, 1H), 6.82 (s, 1H),
7.20 (d, J = 8.1 Hz, 1H); MS (EI) m/z: 248.
4.1.4.4. 4-(6-Amino-1-oxo-1,3-dihydroisoindol-2-yl)butyric acid
methyl ester (5d). Mp = 97–98 C; 1H NMR d (400 MHz,
d6-DMSO) 1.82 (dt, J = 14.2, 7.2 Hz, 2H), 2.30 (t, J = 7.2 Hz, 2H),
3.46 (t, J = 7.2 Hz, 2H), 3.52 (s, 3H), 4.23 (s, 2H), 5.28 (s, 2H), 6.76
(dd, J = 8.1, 2.1 Hz, 1H), 6.81 (d, J = 2.1 Hz, 1H), 7.17 (d, J = 8.1 Hz,
1H); MS (EI) m/z: 248.4.1.5. 1-Boc-4-piperidineacetic acid (6)
1-Boc-piperidine-4-carboxylic acid (2.29 g, 10 mmol) was dis-
solved in anhydrous THF (25 ml) under argon. The solution was
cooled to 15 C, and triethylamine (1.4 ml, 10 mmol), and then
isobutyl chloroformate (1.3 ml, 10 mmol), were added. The reactor
was protected from light. After 30 min, an ethereal solution of
diazomethane was added. The mixture was allowed to warm to
room temperature for 2 h without stirring and was left overnight.
The reaction solution was diluted with chloroform (ﬁnal volume
200 ml). The excess of diazomethane was destroyed by addition
of few drops of acetic acid, and saturated aqueous solution of
NaHCO3 (10 ml) was added carefully. The aqueous layer was sepa-
rated, and the organic layer was washed with saturated aqueous
NaCl (10 ml). The organic layer was dried over anhydrous Na2SO4,
ﬁltered, and the solvent was evaporated in vacuo to dryness. The
crude product, the diazoketone, was used directly in the next step.
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(10 ml) and silver oxide (0.3 g) were added, and the mixture (pro-
tected from light) was stirred for 2–3 h at 45 C (the reaction was
monitored by TLC). Silver oxide was removed by centrifugation
and the supernatant was evaporated in vacuo to dryness. The res-
idue was dissolved in chloroform (100 ml) and the solution was
washed with 5% aqueous solution of NaOH (30 ml). The aqueous
layer was separated and pH of aqueous solution was brought to
three, and the product was extracted with chloroform. The organic
layer was washed with saturated aqueous NaCl (50 ml). The organ-
ic layer was dried over anhydrous Na2SO4, ﬁltered, and chloroform
was evaporated to yield oily residue of 6. After a period of few days,
oil was converted into solid waxy substance.
4.1.6. 2-Acetyl-1,2,3,4-tetrahydroisoquinoline-7-carboxylic (13)
Compound 12 (2.5 g, 0.117 mol) was dissolved in anhydrous
CH2Cl2 (50 ml). The solution was cooled to 10 C, and with inten-
sive stirring oxalyl chloride (5 ml, 0.117 mol) was added. AlCl3
(2.85, 0.643 mol) was added in small portions to the stirred solu-
tion with temperature kept below 9 C. The mixture was stirred
for 1 h at 10 C. Then additional AlCl3 (3.81, 0.643 mol) was
added, and the mixture was stirred for another 2 h at 10 C. The
reaction mixture was allowed to stand overnight at room temper-
ature and then poured onto ice (100 g). The aqueous phase was ex-
tracted with CH2Cl2 (100 ml). The organic phase was dried with
anhydrous Na2SO4, ﬁltered, and the solvent was evaporated in va-
cuo. The residue was dissolved in acid, with stirring and heating
(40 C). To the warm solution, ice was added. pH of the mixture
was brought to three and the product was extracted with chloro-
form. The chloroform phase was dried with anhydrous Na2SO4, ﬁl-
tered, and the solvent was evaporated in vacuo to dryness. The
resulting 13 obtained as a solid residue was used in subsequent
transformations without further puriﬁcation. Cream powder, yield
53%. Mp = 183.5–184.5 C.
4.1.7. General procedure for a preparation of compound 15
The 10 mmol of acid (6–8, 11a,b or 14) was dissolved in anhy-
drous acetonitryle (25 ml). The solution was cooled to 5 C, and
triethylamine (1.4 ml, 10 mmol), and then HBTU (3.79 g, 10 mmol)
or HATU (3.8 g, 10 mmol), were added. The mixture was stirred for
1 h at 5 C and then 10 mmol of amine 5 was added. The reaction
mixture was allowed to stand overnight at room temperature. The
residual amount of the activated ether (Bt- or At-ether of starting
acid) was destroyed by addition of few drops of N,N-dimethylpro-
pane-1,3-diamine, and the solvent was evaporated in vacuo to dry-
ness. The residue was dissolved in 100 ml of chloroform. The
solution was washed with water (40 mL), aqueous solution of
1 M HCl (40 ml) and 5% aqueous solution of NaHCO3 (40 ml). The
organic layer was dried over Na2SO4, ﬁltered off, and the solvent
was evaporated in vacuo to dryness. The resulting residue was trit-
urated with warm hexane (20 ml), and the precipitate was col-
lected by ﬁltration and dried.
4.1.7.1. {6-[2-(1-Boc-piperidin-4-yl)acetylamino]-1-oxo-1,3-dihyd-
roisoindol-2-yl}acetic acid methyl ester (15a). Mp = 193–
195 C; 1H NMR d (400 MHz, d6-DMSO) 1.07 (ddd, J = 24.3, 12.1,
3.9 Hz, 2H), 1.38 (s, 9H), 1.65 (d, J = 11.0 Hz, 2H), 1.94 (m,
J = 3.7 Hz, 1H), 2.27 (d, J = 6.8 Hz, 2H), 2.64–286 (m, 2H), 3.67 (s,
3H), 3.90 (d, J = 11.7 Hz, 2H), 4.37 (s, 2H), 4.45 (s, 2H), 7.52 (d,
J = 8.1 Hz, 1H), 7.68 (dd, J = 8.3, 2.0 Hz, 1H), 8.07 (d, J = 1.2 Hz, 1H),
10.13 (s, 1H); HRMS (FAB) m/z calcd for C23H33N3O6 [M+H]+:
446.5280, found: 446.5273.
4.1.7.2. {6-[4-(1-Boc-piperidin-4-yl)butyrylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}acetic acid methyl ester (15b). Mp = 149–
150 C; 1H NMR d (400 MHz, d6-DMSO) 0.95 (ddd, J = 24.3, 12.2,4.0 Hz, 2H), 1.24 (dd, J = 14.9, 6.6 Hz, 2H), 1.39 (s, 9H), 1.41–1.50
(m, 1H), 1.59–1.67 (m, 4H), 2.33 (t, J = 7.3 Hz, 2H), 2.60–2.75 (m,
2H), 3.69 (s, 3H), 3.92 (d, J = 11.0 Hz, 2H), 4.39 (s, 2H), 4.46 (s, 2H),
7.54 (d, J = 8.2 Hz, 1H), 7.72 (dd, J = 8.2, 1.8 Hz, 1H), 8.08 (d,
J = 1.8 Hz, 1H), 10.13 (s, 1H); HRMS (FAB)m/z calcd for C25H36N3O6
[M+H]+: 474.5822, found: 474.5826.
4.1.7.3. {6-[4-(1-Boc-piperidin-4-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}acetic acid methyl ester (15C). Mp = 189–
191 C; 1H NMR d (400 MHz, d6-DMSO) 1.43 (s, 9H), 1.55 (ddd,
J = 24.9, 12.4, 3.8 Hz, 2H), 1.79 (d, J = 12.7 Hz, 2H), 2.75–2.90 (m,
3H), 4.10 (d, J = 10.8 Hz, 2H), 4.29 (s, 2H), 4.50 (s, 2H), 7.44 (d,
J = 7.6 Hz, 2H), 7.59 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 7.3 Hz, 2H), 7.97
(d, J = 8.3 Hz, 1H), 8.22 (s, 1H), 10.41 (s, 1H); HRMS (FAB)m/z calcd
for C28H34N3O6 [M+H]+: 508.5997, found: 508.6002.
4.1.7.4. {6-[4-(4-Boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}acetic acid methyl ester (15d). Mp = 219–
220.5 C; 1H NMR d (500 MHz, d6-DMSO) 1.44 (s, 9H), 3.31 (t,
J = 4.6 Hz, 4H), 3.48 (t, J = 4.6 Hz, 4H), 3.70 (s, 3H), 4.41 (s, 2H), 4.50
(s, 2H), 7.05 (d, J = 8.7 Hz, 2H), 7.58 (d, J = 8.2 Hz, 1H), 7.93 (d,
J = 8.7 Hz, 2H), 7.98 (dd, J = 8.2, 1.0 Hz, 1H), 8.23 (d, J = 1.0, 1H),
10.18 (s, 1H); HRMS (FAB) m/z calcd for C27H33N4O6 [M+H]+:
509.5873, found: 509.5880.
4.1.7.5. {6-[(2-Boc-1,2,3,4-tetrahydroisoquinoline-7-carbonyl)-
amino]-1-oxo-1,3-dihydroisoindol-2-yl}acetic acid methyl ester
(15e). Mp = 134–137 C; 1H NMR d (400 MHz, d6-DMSO) 1.45 (s,
9H), 2.87 (t, J = 5.8 Hz, 2H), 3.60 (t, J = 5.8 Hz, 2H), 3.70 (s, 3H), 4.42
(s, 2H), 4.51 (s, 2H), 4.61 (s, 2H), 7.35 (d, J = 8.1 Hz, 1H), 7.61 (d,
J = 8.3 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.83 (s, 1H), 8.00 (dd, J = 8.2,
1.7 Hz, 1H), 8.24 (d, J = 1.7 Hz, 1H), 10.41 (s, 1H); HRMS (FAB) m/z
calcd for C26H30N3O6 [M+H]+: 480.5455, found: 480.5447.
4.1.7.6. 3-{6-[2-(1-Boc-piperidin-4-yl)acetylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}propionic acid methyl ester (15f).
Mp = 168–170 C; 1H NMR d (500 MHz, d6-DMSO) 1.09 (ddd,
J = 23.9, 11.7, 3.9 Hz, 2H), 1.40 (s, 9H), 1.67 (d, J = 11.7 Hz, 2H),
1.94–1.98 (m, 1H), 2.28 (d, J = 6.7 Hz, 2H), 2.70 (t, J = 6.7 Hz, 2H),
2.74–2.80 (m, 2H), 3.61 (s, 3H), 3.76 (t, J = 6.7 Hz, 2H), 3.92 (d,
J = 9.1 Hz, 2H), 4.43 (s, 5H), 7.50 (d, J = 8.3 Hz, 1H), 7.68 (d,
J = 8.3 Hz, 1H), 8.04 (s, 1H), 10.12 (s, 1H); HRMS (FAB) m/z calcd
for C24H34N3O6 [M+H]+: 460.5551, found: 460.5560.
4.1.7.7. 3-{6-[4-(1-Boc-piperidin-4-yl)butyrylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}propionic acid methyl ester
(15g). Mp = 171–172 C; 1H NMR d (400 MHz, d6-DMSO) 0.94
(ddd, J = 24.2, 12.2, 4.2 Hz, 2H), 1.23 (dd, J = 15.2, 6.8 Hz, 2H), 1.38
(s, 9H), 1.40–1.45 (m, 1H), 1.58–1.65 (m, 4H), 2.31 (t, J = 7.5 Hz,
2H), 2.58–2.65 (m, 2H), 2.68 (t, J = 7.0 Hz, 2H), 3.60 (s, 3H), 3.74 (t,
J = 7.0 Hz, 2H), 3.91 (d, J = 12.5 Hz, 2H), 4.41 (s, 2H), 7.49 (d,
J = 8.2 Hz, 1H), 7.67 (dd, J = 8.2, 1.7 Hz, 1H), 8.02 (d, J = 1.7 Hz, 1H),
10.08 (s, 1H); HRMS (FAB) m/z calcd for C26H38N3O6 [M+H]+:
488.6093, found: 488.6087.4.1.7.8. 3-{6-[4-(1-Boc-piperidin-4-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}propionic acid methyl ester
(15h). Mp = 199.5–200.5 C; 1H NMR d (400 MHz, d6-DMSO)
1.41 (s, 9H), 1.52 (ddd, J = 25.2, 12.6, 4.0 Hz, 2H), 1.77 (d,
J = 12.6 Hz, 2H), 2.69 (t, J = 7.0 Hz, 2H), 2.73–2.90 (m, 3H), 3.59 (s,
3H), 3.75 (t, J = 7.0 Hz, 2H), 4.08 (d, J = 11.5 Hz, 2H), 4.44 (s, 2H),
7.41 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 8.3 Hz, 1H), 7.90 (d, J = 8.1 Hz,
2H), 7.92 (dd, J = 8.3, 1.7 Hz, 1H), 8.16 (d, J = 1.7 Hz, 1H), 10.36 (s,
1H); HRMS (FAB) m/z calcd for C29H36N3O6 [M+H]+: 522.6268,
found: 522.6260.
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dihydroisoindol-2-yl}propionic acid methyl ester (15i). Mp= 185–
187 C; 1H NMR d (400MHz, d6-DMSO) 1.43 (s, 9H), 2.71 (t, J = 6.9Hz,
2H), 3.30 (s, 4H), 3.48 (s, 4H), 3.61 (s, 3H), 3.77 (t, J = 6.9Hz, 2H), 4.45 (s,
2H), 7.04 (d, J = 9.0 Hz, 2H), 7.54 (d, J = 8.7Hz, 1H), 7.91 (d, J = 9.0Hz,
2H), 7.95 (dd, J = 8.7, 1.7 Hz, 1H), 8.18 (d, J = 1.7Hz, 1H), 10.15 (s,
1H); HRMS (FAB) m/z calcd for C28H35N4O6 [M+H]+: 523.6144, found:
523.6137.
4.1.7.10. 3-{6-[(2-Boc-1,2,3,4-tetrahydroisoquinoline-7-carbonyl)
amino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid methyl
ester (15j). Mp = 102–103 C; 1H NMR d (400 MHz, d6-DMSO)
1.45 (s, 9H), 2.72 (t, J = 7.5 Hz, 2H), 2.87 (t, J = 5.9 Hz, 2H), 3.60 (t,
J = 5.6 Hz, 2H), 3.62 (s, 3H), 3.78 (t, J = 7.0 Hz, 2H), 4.47 (s, 2H),
4.61 (s, 2H), 7.34 (d, J = 8.1 Hz, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.80
(d, J = 8.1 Hz, 1H), 7.82 (s, 1H), 7.95 (dd, J = 8.1, 1.5 Hz, 1H), 8.19
(d, J = 1.5 Hz, 1H), 10.37 (s, 1H); HRMS (FAB) m/z calcd for
C27H32N3O6 [M+H]+: 494.5726, found: 494.5730.
4.1.7.11. 3-{6-[3-(4-Boc-piperazin-1-yl)benzoylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}propionic acid methyl ester
(15k). Mp = 181–183 C; 1H NMR d (500 MHz, d6-DMSO)
1.44 (s, 9H), 2.72 (t, J = 6.5 Hz, 2H), 3.21 (s, 4H), 3.50 (s, 4H), 3.62
(s, 3H), 3.78 (t, J = 6.1 Hz, 2H), 4.47 (s, 2H), 7.19 (d, J = 6.2 Hz,
1H), 7.38–7.44 (m, 2H), 7.50 (s, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.95
(d, J = 8.0 Hz, 1H), 8.17 (m, 1H), 10.35 (s, 1H); HRMS (FAB) m/z
calcd for C28H35N4O6 [M+H]+: 523.6144, found: 523.6146.
4.1.7.12. 3-{6-[2-(1-Boc-piperidin-4-yl)acetylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}butyric acid methyl ester (15l). Mp = 130–
132 C; 1H NMR d (500 MHz, d6-DMSO) 1.09 (ddd, J = 22.5, 11.7,
3.1 Hz, 2H), 1.28 (d, J = 5.7 Hz, 3H), 1.40 (s, 9H), 1.67 (d, J = 11.7 Hz,
2H), 1.91–2.00 (m, 1H), 2.27 (d, J = 6.2 Hz, 2H), 2.65–2.82 (m, 4H),
3.56 (s, 3H), 3.93 (d, J = 8.3 Hz, 2H), 4.38 (dd, J = 22.8, 17.1 Hz, 2H),
4.60 (m, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 8.03 (s,
1H), 10.10 (s, 1H); HRMS (FAB) m/z calcd for C25H36N3O6 [M+H]+:
474.5822, found: 474.5823.
4.1.7.13. 3-{6-[4-(1-Boc-piperidin-4-yl)butyrylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}butyric acid methyl ester
(15m). Mp = 133–134 C; 1H NMR d (500 MHz, d6-DMSO) 0.95
(ddd, J = 24.0, 12.2, 3.9 Hz, 2H), 1.22–1.25 (m, 2H), 1.28 (d,
J = 6.6 Hz, 3H), 1.39 (s, 9H), 1.61–1.66 (m, 4H), 2.32 (t, J = 7.3 Hz,
2H), 2.65–2.77 (m, 4H), 3.56 (s, 3H), 3.92 (d, J = 9.3 Hz, 2H), 4.38
(dd, J = 24.0, 17.1 Hz, 2H), 4.61 (td, J = 13.7, 6.8 Hz, 1H), 7.50 (d,
J = 8.3 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 8.02 (s, 1H), 10.07 (s, 1H);
HRMS (FAB) m/z calcd for C27H40N3O6 [M+H]+: 502.6364, found:
502.6367.
4.1.7.14. 3-{6-[4-(1-Boc-piperidin-4-yl)benzoylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}butyric acid methyl ester (15n). 1H
NMR d (500 MHz, d6-DMSO) 1.30 (d, J = 6.8 Hz, 3H), 1.43 (s, 9H),
1.55 (ddd, J = 24.5, 11.7, 2.9 Hz, 2H), 1.79 (d, J = 11.7 Hz, 2H), 2.68–
2.85 (m, 5H), 3.57 (s, 3H), 4.11 (d, J = 7.6 Hz, 2H), 4.42 (dd, J = 24.0,
17.6 Hz, 2H), 4.63 (dt, J = 13.9, 6.7 Hz, 1H), 7.43 (d, J = 8.1 Hz, 2H),
7.57 (d, J = 8.1 Hz, 1H), 7.92–7.96 (m, 3H), 8.18 (s, 1H), 10.38 (s,
1H); HRMS (FAB) m/z calcd for C30H38N3O6 [M+H]+: 536.6539,
found: 536.6535
4.1.7.15. 3-{6-[4-(1-Boc-piperazin-4-yl)benzoylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}butyric acid methyl ester
(15o). Mp = 95–97 C (decomposes); 1H NMR d (500 MHz, d6-
DMSO) 1.29 (d, J = 6.8 Hz, 3H), 1.44 (s, 9H), 2.68–2.78 (m, 2H), 3.30
(t, J = 4.0 Hz, 4H), 3.48 (t, J = 4.0 Hz, 4H), 3.57 (s, 3H), 4.41 (dd,
J = 24.2, 17.4 Hz, 2H), 4.63 (td, J = 13.9, 6.5 Hz, 1H), 7.05 (d,
J = 9.0 Hz, 2H), 7.55 (d, J = 8.2 Hz, 1H), 7.92 (d, J = 9.0 Hz, 2H),7.95 (dd, J = 8.2, 1.8 Hz, 1H), 8.17 (d, J = 1.8 Hz, 1H), 10.15 (s, 1H);
HRMS (FAB) m/z calcd for C29H37N4O6 [M+H]+: 537.6414, found:
537.66417.
4.1.7.16. 3-{6-[(2-Boc-1,2,3,4-tetrahydroisoquinoline-7-carbonyl)-
amino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid methyl
ester (15p). 1H NMR d (400 MHz, d6-DMSO + CCl4) 1.29 (d,
J = 6.6 Hz, 3H), 1.45 (s, 9H), 2.67–2.77 (m, 2H), 2.86 (t, J = 5.0 Hz,
2H), 3.57 (s, 3H), 3.58–3.60 (m, 2H), 4.40 (dd, J = 22.0, 17.4 Hz,
2H), 4.59–4.66 (m, 3H), 7.33 (d, J = 7.5 Hz, 1H), 7.57 (d, J = 8.3 Hz,
1H), 7.79–7.82 (m, 2H), 7.95 (d, J = 7.9 Hz, 1H), 8.18 (s, 1H), 10.36
(s, 1H); HRMS (FAB) m/z calcd for C28H34N3O6 [M+H]+: 508.5997,
found: 508.5995.
4.1.7.17. 3-{6-[3-(4-Boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}butyric acidmethyl ester (15q). Mp = 142–
143.5 C; 1H NMR d (400 MHz, d6-DMSO) 1.30 (d, J = 6.7 Hz, 3H),
1.44 (s, 9H), 2.68–2.79 (m, 2H), 3.24 (s, 4H), 3.53 (s, 4H), 3.57 (s,
3H), 4.43 (dd, J = 24.4, 17.1 Hz, 2H), 4.63 (m, 1H), 7.25 (d, J = 7.8 Hz,
1H), 7.41 (t, J = 7.8 Hz, 1H), 7.47 (d, J = 7.5 Hz, 1H), 7.58 (d,
J = 7.0 Hz, 2H), 7.98 (d, J = 8.0 Hz, 1H), 8.17 (s, 1H), 10.40 (s, 1H);
HRMS (FAB) m/z calcd for C29H37N4O6 [M+H]+: 537.6414, found:
537.66416.
4.1.7.18. 4-{6-[2-(1-Boc-piperidin-4-yl)acetylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}butyric acidmethyl ester (15r). Mp = 159–
160 C; 1H NMR d (500 MHz, d6-DMSO) 1.06–1.12 (m, 2H), 1.40 (s,
9H), 1.67 (d, J = 11.7 Hz, 2H), 1.87 (t, J = 6.8, 2H), 1.92–1.99 (m, 1H),
2.28 (d, J = 6.5, 2H), 2.34 (t, J = 6.8, 2H), 2.65–2.80 (m, 2H), 3.52–
3.56 (m, 5H), 3.92 (d, J = 8.6 Hz, 2H), 4.40 (s, 2H), 7.50 (d, J = 7.9 Hz,
1H), 7.68 (d, J = 7.9 Hz, 1H), 8.03 (s, 1H), 10.09 (s, 1H); HRMS (FAB)
m/z calcd for C25H36N3O6 [M+H]+: 474.5822, found: 474.5819.
4.1.7.19. 4-{6-[4-(1-Boc-piperidin-4-yl)butyrylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}butyric acid methyl ester
(15s). Mp = 151–153 C; 1H NMR d (400 MHz, d6-DMSO)
0.94 (ddd, J = 24.4, 12.2, 4.0 Hz, 2H), 1.23 (dd, J = 15.7, 7.3 Hz,
2H), 1.38 (s, 9H), 1.41–1.43 (m, 1H), 1.60–1.66 (m, 4H), 1.86 (dt,
J = 14.2, 7.1 Hz, 2H), 2.32 (m, J = 7.1 Hz, 4H), 2.59–2.73 (m, 2H),
3.52 (t, J = 7.1 Hz, 2H), 3.53 (s, 3H), 3.91 (d, J = 11.7 Hz, 2H), 4.39
(s, 2H), 7.49 (d, J = 8.1 Hz, 1H), 7.68 (dd, J = 8.1, 1.6 Hz, 1H), 8.2
(d, J = 1.6 Hz, 1H), 10.07 (s, 1H); HRMS (FAB) m/z calcd for
C27H40N3O6 [M+H]+: 502.6364, found: 502.6363.
4.1.7.20. 4-{6-[4-(1-Boc-piperidin-4-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}butyric acid methyl ester (15t). Mp = 166–
167 C; 1H NMR d (400 MHz, d6-DMSO) 1.4 (s, 9H) 1.5 (ddd,
J = 22.3, 12.0, 2.4 Hz, 2H) 1.8 (d, J = 12.2 Hz, 2H) 1.9 (dt, J = 13.4,
6.6 Hz, 2H) 2.3 (t, J = 6.6 Hz, 2H) 2.8 (m, 3H) 3.5 (m, 5H) 4.1 (d,
J = 9.0 Hz, 2H) 4.4 (s, 2H) 7.4 (d, J = 7.3 Hz, 2H) 7.5 (d, J = 8.1 Hz, 1H)
7.9 (m, J = 6.7, 6.7 Hz, 3H) 8.2 (s, 1H) 10.4 (s, 1H); HRMS (FAB) m/z
calcd for C30H38N3O6 [M+H]+: 536.6539, found: 536.6537.
4.1.7.21. 4-{6-[(2-Boc-1,2,3,4-tetrahydroisoquinoline-7-carbonyl)-
amino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid methyl
ester (15u). Mp = 142–145 C; 1H NMR d (400 MHz, d6-
DMSO) 1.44 (s, 9H), 1.88 (dt, J = 13.8, 6.6 Hz, 4H), 2.35 (t,
J = 7.1 Hz, 2H), 2.86 (t, J = 4.9, 2H), 3.54 (s, 3H), 3.59 (t, J = 4.9,
4H), 4.44 (s, 2H), 4.60 (s, 2H), 7.33 (d, J = 7.6 Hz, 1H), 7.56 (d,
J = 8.1 Hz, 2H), 7.78–7.81 (m, 2H), 7.94 (d, J = 8.1 Hz, 1H), 8.18 (s,
1H), 10.37 (s, 1H); HRMS (FAB) m/z calcd for C28H34N3O6 [M+H]+:
508.5997, found: 508.5995.
4.1.8. General procedure for a preparation of compound 16
The compound 15 (10 mmol) was dissolved in methanol
(25 ml), and to this solution was added 1 M NaOH aqueous solu-
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overnight. Then chloroform (50 ml) was added, and pH of the mix-
ture was brought to three with intensive stirring. When the prod-
uct was not soluble in chloroform layer, an suspension was formed,
the product was ﬁltered off. The precipitate was washed (on the ﬁl-
ter) with water, chloroform and ether, and dried in air. Thus ob-
tained product 16 was not need to be further puriﬁed. When the
reaction product was soluble in chloroform, the chloroform phase
was collected and washed with water (20 ml). The chloroform
phase was dried with anhydrous Na2SO4, ﬁltered, and the solvent
was evaporated in vacuo to dryness. The resulting residue was trit-
urated with ether (20 ml) and the precipitate was collected by ﬁl-
tration and dried in air.
4.1.8.1. {6-[2-(1-Boc-piperidin-4-yl)acetylamino]-1-oxo-1,3-dihyd-
roisoindol-2-yl}acetic acid (16a). Mp = 198–201 C; 1H NMR d
(400MHz, d6-DMSO) 1.07 (ddd, J = 23.6, 11.9, 3.2 Hz, 2H), 1.38 (s,
9H), 1.65 (d, J = 12.2 Hz, 2H), 1.91–197 (m, 1H), 2.26 (d, J = 6.8 Hz,
2H), 2.65–2.80 (m, 2H), 3.91 (d, J = 11.0 Hz, 2H), 4.25 (s, 2H), 4.44 (s,
2H), 7.51 (d, J = 8.3 Hz, 1H), 7.68 (d, J = 7.8 Hz, 1H), 8.06 (s, 1H),
10.13 (s, 1H), 12.86 (br s, 1H); HRMS (FAB) m/z calcd for
C22H30N3O6 [M+H]+: 432.5009, found: 432.5005.
4.1.8.2. {6-[4-(1-Boc-piperidin-4-yl)butyrylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}acetic acid (16b). Mp = 165.5–167 C;
1H NMR d (400 MHz, d6-DMSO) 0.95 (ddd, J = 24.3, 12.3, 4.0 Hz,
2H), 1.22–1.27 (m, 2H), 1.39 (s, 9H), 1.42–1.45 (m, 1H), 1.59–168
(m, 4H), 2.33 (t, J = 7.5 Hz, 2H), 2.60–2.75 (m, 2H), 3.93 (d,
J = 11.2 Hz, 2H), 4.27 (s, 2H), 4.46 (s, 2H), 7.53 (d, J = 8.1 Hz, 1H),
7.71 (dd, J = 8.3, 1.7 Hz, 1H), 8.08 (d, J = 1.5 Hz, 1H), 10.12 (s, 1H),
12.96 (br s, 1H); HRMS (FAB) m/z calcd for C24H32N3O6 [M+H]+:
460.5551, found: 460.5559.
4.1.8.3. {6-[4-(1-Boc-piperidin-4-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}acetic acid (16C). Mp = 223–225 C;
1H NMR d (400 MHz, d6-DMSO) 1.43 (s, 9H), 1.53 (ddd, J = 24.9,
12.4, 3.8 Hz, 2H), 1.79 (d, J = 12.7 Hz, 2H), 2.77–2.85 (m, 3H), 4.11
(d, J = 10.8 Hz, 2H), 4.30 (s, 2H), 4.50 (s, 2H), 7.44 (d, J = 7.6 Hz,
2H), 7.59 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 7.3 Hz, 2H), 7.97 (d,
J = 8.3 Hz, 1H), 8.27 (s, 1H), 10.41 (s, 1H); HRMS (FAB) m/z calcd
for C27H32N3O6 [M+H]+: 494.5726, found: 494.5721.
4.1.8.4. {6-[4-(4-Boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}acetic acid (16d). Mp = 215–216.5 C
(decomposes); 1H NMR d (500 MHz, d6-DMSO) 1.44 (s, 9H), 3.31
(s, 4H), 3.48 (s, 4H), 4.29 (s, 2H), 4.49 (s, 2H), 7.05 (d, J = 8.3 Hz,
2H), 7.56 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.98 (d,
J = 8.3 Hz, 1H), 8.23 (s, 1H), 10.17 (s, 1H), 12.97 (br s, 1H); HRMS
(FAB) m/z calcd for C26H31N4O6 [M+H]+: 495.5602, found:
495.5610.
4.1.8.5. {6-[(2-Boc-1,2,3,4-tetrahydroisoquinoline-7-carbonyl)amino]-
1-oxo-1,3-dihydroisoindol-2-yl}acetic acid (16e). Mp = 218–
220 C (decomposes); 1H NMR d (400 MHz, d6-DMSO) 1.45 (s,
9H), 2.87 (t, J = 5.7 Hz, 2H), 3.60 (t, J = 5.7 Hz, 2H), 4.29 (s, 2H),
4.50 (s, 2H), 4.61 (s, 2H), 7.35 (d, J = 8.1 Hz, 1H), 7.60 (d,
J = 8.3 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.83 (s, 1H), 7.98 (dd,
J = 8.3, 2.0 Hz, 1H), 8.23 (d, J = 1.7 Hz, 1H), 10.41 (s, 1H), 12.96 (br
s, 1H); HRMS (FAB) m/z calcd for C25H28N3O6 [M+H]+: 466.5184,
found: 466.5187.
4.1.8.6. 3-{6-[2-(1-Boc-piperidin-4-yl)acetylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}propionic acid (16f). Mp = 193–
194 C; 1H NMR d (400 MHz, d6-DMSO) 1.08 (ddd, J = 24.6, 12.4,
3.3 Hz, 2H), 1.40 (s, 9H), 1.66 (d, J = 11.5 Hz, 2H), 1.90–2.01 (m,
1H), 2.28 (d, J = 7.1 Hz, 2H), 2.60 (t, J = 7.0 Hz, 2H), 2.66–2.82 (m,2H), 3.72 (t, J = 7.1 Hz, 2H), 3.92 (d, J = 11.7 Hz, 2H), 4.43 (s, 2H),
7.51 (d, J = 8.1 Hz, 1H), 7.67 (dd, J = 8.1, 1.2 Hz, 1H), 8.04 (d,
J = 1.2 Hz, 1H), 10.11 (s, 1H), 12.36 (br s, 1H); HRMS (FAB)m/z calcd
for C23H32N3O6 [M+H]+: 446.5280, found: 546.5274.
4.1.8.7. 3-{6-[4-(1-Boc-piperidin-4-yl)butyrylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}propionic acid (16g). Mp = 176.5–
177.5 C; 1H NMR d (400 MHz, d6-DMSO) 0.93 (ddd, J = 23.0, 10.5,
3.2 Hz, 2H), 1.22 (dd, J = 14.2, 6.9 Hz, 2H), 1.36 (s, 9H), 1.49–1.46
(m, 1H), 1.57–1.64 (m, 4H), 2.30 (t, J = 7.3 Hz, 2H), 2.58 (t,
J = 6.9 Hz, 2H), 2.62–2.76 (m, 2H), 3.69 (t, J = 6.9 Hz, 2H), 3.90 (d,
J = 10.5 Hz, 2H), 4.41 (s, 2H), 7.48 (d, J = 8.1 Hz, 1H), 7.66 (dd,
J = 8.1, 1.5 Hz, 1H), 8.01 (d, J = 1.5 Hz, 1H), 10.10 (s, 1H), 12.34 (br
s, 1H); HRMS (FAB) m/z calcd for C25H36N3O6 [M+H]+: 474.5822,
found: 508.5828.
4.1.8.8. 3-{6-[4-(1-Boc-piperidin-4-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}propionic acid (16h). Mp = 195–196 C; 1H
NMR d (400 MHz, d6-DMSO) 1.41 (s, 9H), 1.52 (ddd, J = 25.1,
12.6, 3.9 Hz, 2H), 1.77 (d, J = 12.5 Hz, 2H), 2.60 (t, J = 7.1 Hz,
2H), 2.74–2.85 (m, 3H), 3.72 (t, J = 7.0 Hz, 2H), 4.08 (d, J = 10.3 Hz,
2H), 4.45 (s, 2H), 7.41 (d, J = 8.3 Hz, 2H), 7.54 (d,
J = 8.1 Hz, 1H), 7.90 (d, J = 8.3 Hz, 2H), 7.92 (dd, J = 8.1, 1.7 Hz, 1H),
8.17 (d, J = 1.7 Hz, 1H), 10.37 (s, 1H), 12.37 (br s, 1H); HRMS
(FAB) m/z calcd for C28H34N3O6 [M+H]+: 508.5997, found:
508.6002.
4.1.8.9. 3-{6-[4-(4-Boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}propionic acid (16i). Mp >300 C (decom-
poses); 1H NMR d (400MHz, d6-DMSO) 1.43 (s, 9H), 2.62 (t,
J = 6.0 Hz, 2H), 3.30 (s, 4H), 3.48 (s, 4H), 3.74 (t, J = 6.0 Hz, 2H), 4.46
(s, 2H), 7.04 (d, J = 7.9 Hz, 2H), 7.54 (d, J = 7.5 Hz, 1H), 7.91–7.95 (m,
2H), 8.18 (s, 1H), 10.15 (s, 1H), 12.35 (br s, 1H); HRMS (FAB) m/z calcd
for C27H33N4O6 [M+H]+: 509.5873, found: 509.5870.
4.1.8.10. 3-{6-[(2-Boc-1,2,3,4-tetrahydroisoquinoline-7-carbonyl)
amino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid (16j)
Mp = 118–120 C (decomposes); 1H NMR d (400MHz, d6-DMSO) 1.45
(s, 9H), 2.63 (t, J = 7.1 Hz, 2H), 2.87 (t, J = 5.7 Hz, 2H), 3.60 (t,
J = 5.5 Hz, 2H), 3.75 (t, J = 7.0 Hz, 2H), 4.48 (s, 2H), 4.61 (s, 2H), 7.34
(d, J = 8.1 Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.83
(s, 1H), 7.95 (dd, J = 8.2, 1.6 Hz, 1H), 8.19 (d, J = 1.6 Hz, 1H), 10.38 (s,
1H), 12.35 (br s, 1H); HRMS (FAB) m/z calcd for C26H30N3O6 [M+H]+:
480.5455, found: 480.5457.
4.1.8.11. 3-{6-[3-(4-Boc-piperazin-1-yl)benzoylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}propionic acid (16k). Mp = 196–
196.5 C; 1H NMR d (500 MHz, d6-DMSO) 1.43 (s, 9H), 2.53–
2.54 (m, 2H), 3.21 (t, J = 6.4 Hz, 4H), 3.49 (t, J = 6.4 Hz, 4H),
3.72 (t, J = 6.8 Hz, 2H), 4.48 (s, 2H), 7.18 (d, J = 7.6 Hz, 1H),
7.38 (t, J = 7.8 Hz, 1H), 7.44 (d, J = 7.3 Hz, 1H), 7.53–7.56 (m,
2H), 7.98 (d, J = 8.1 Hz, 1H), 8.19 (s, 1H), 10.49 (s, 1H); HRMS
(FAB) m/z calcd for C27H33N4O6 [M+H]+: 509.5873, found:
509.5879.
4.1.8.12. 3-{6-[2-(1-Boc-piperidin-4-yl)acetylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}butyric acid (16l). Mp = 197–199 C;
1H NMR d (500 MHz, d6-DMSO) 1.09 (ddd, J = 23.6, 11.9, 3.1 Hz,
2H), 1.27 (d, J = 6.5 Hz, 3H), 1.40 (s, 9H), 1.67 (d, J = 12.2 Hz, 2H),
1.91–2.02 (m, 1H), 2.28 (d, J = 7.3 Hz, 2H), 2.62 (ddd, J = 31.5,
15.2, 7.3 Hz, 2H), 2.69–2.80 (m, 2H), 3.92 (d, J = 9.1 Hz, 2H), 4.39
(dd, J = 27.5, 17.4 Hz, 2H), 4.60 (td, J = 13.1, 6.0 Hz, 1H), 7.51 (d,
J = 8.3 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 8.02 (s, 1H), 10.09 (s, 1H),
12.26 (s, 1H); HRMS (FAB) m/z calcd for C24H34N3O6 [M+H]+:
460.5551, found: 450.5555.
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1,3-dihydroisoindol-2-yl}butyric acid (16m). Mp = 139–
140.5 C; 1H NMR d (500 MHz, d6-DMSO) 0.95 (ddd, J = 24.5, 12.2,
3.7 Hz, 2H), 1.20–1.25 (m, 5H), 1.39 (s, 9H), 1.42–1.44 (m, 1H),
1.59–1.65 (m, 4H), 2.32 (t, J = 7.1 Hz, 2H), 2.62–2.69 (m, 2H), 3.92
(d, J = 8.1 Hz, 2H), 4.36 (s, 2H), 4.59 (m, 1H), 7.46 (d, J = 7.8 Hz, 1H),
7.69 (d, J = 7.8 Hz, 1H), 8.03 (s, 1H), 10.23 (s, 1H); HRMS (FAB) m/z
calcd for C26H38N3O6 [M+H]+: 488.6093, found: 488.6089.
4.1.8.14. 3-{6-[4-(1-Boc-piperidin-4-yl)benzoylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}butyric acid (16n). Mp = 175–176 C;
1H NMR d (500 MHz, d6-DMSO) 1.25 (d, J = 6.4 Hz, 3H), 1.43 (s, 9H),
1.54 (ddd, J = 24.8, 12.2, 3.5 Hz, 2H), 1.79 (d, J = 12.2 Hz, 2H), 2.74–
2.89 (m, 3H), 4.10 (d, J = 6.4 Hz, 2H), 4.41 (s, 2H), 4.62 (dt, J = 13.5,
6.5 Hz, 1H), 7.42 (d, J = 7.8 Hz, 2H), 7.55 (d, J = 8.3 Hz, 1H), 7.93–
7.96 (m, 3H), 8.18(s, 1H), 10.43 (s, 1H); HRMS (FAB) m/z calcd for
C29H36N3O6 [M+H]+: 522.6268, found: 522.6270.
4.1.8.15. 3-{6-[4-(4-Boc-piperazin-1-yl)benzoylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}butyric acid (16o). Mp = 155.5–
156 C; 1H NMR d (500 MHz, d6-DMSO) 1.29 (d, J = 6.6 Hz, 3H),
1.44 (s, 9H), 2.64 (ddd, J = 32.3, 15.3, 7.5 Hz, 2H), 3.30 (s, 4H), 3.48
(s, 4H), 4.41 (dd, J = 27.1, 17.1 Hz, 2H), 4.62 (td, J = 13.8, 7.0 Hz, 1H),
7.04 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.1 Hz,
2H), 7.95 (d, J = 8.8 Hz, 1H), 8.18 (s, 1H), 10.16 (s, 1H), 12.27 (br s,
1H); HRMS (FAB) m/z calcd for C28H35N4O6 [M+H]+: 523.6144,
found: 523.6139.
4.1.8.16. 3-{6-[(2-Boc-1,2,3,4-tetrahydroisoquinoline-7-carbonyl)-
amino]-1-oxo-1,3-dihydroisoindol-2-yl}-butyric acid
(16p). Mp = 153–154 C; 1H NMR d (500 MHz, d6-DMSO) 1.29
(d, J = 6.6 Hz, 3H), 1.45 (s, 9H), 2.64 (ddd, J = 32.8, 15.2, 7.5 Hz, 2H),
2.87 (t, J = 5.2 Hz, 2H), 3.60 (t, J = 5.2 Hz, 2H), 4.43 (dd, J = 27.1,
17.4 Hz, 2H), 4.55–4.64 (m, 3H), 7.34 (d, J = 7.8 Hz, 1H), 7.57
(d, J = 8.3 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.83 (s, 1H), 7.95 (dd,
J = 8.1, 1.5 Hz, 2H), 8.18 (s, 1H) 10.36 (s, 1H), 12.30 (br s, 1H);
HRMS (FAB) m/z calcd for C27H32N3O6 [M+H]+: 494.5726, found:
493.5723.
4.1.8.17. 3-{6-[3-(4-Boc-piperazin-1-yl)benzoylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}butyric acid (16q). Mp >300 C; 1H
NMR d (500 MHz, d6-DMSO) 1.29 (d, J = 3.9 Hz, 3H), 1.44 (s, 9H),
2.65 (ddd, J = 33.2, 18.0, 6.4 Hz, 2H), 3.22 (s, 4H), 3.51 (s, 4H), 4.43
(dd, J = 26.2, 16.1 Hz, 2H), 4.62 (td, J = 14.1, 6.2 Hz, 1H), 7.20 (d,
J = 4.4 Hz, 1H), 7.38–7.43 (m, 2H), 7.51 (s, 1H), 7.58 (d, J = 6.5 Hz,
1H), 7.95 (d, J = 7.0 Hz, 1H), 8.16 (s, 1H), 10.35 (s, 1H), 12.30 (br s,
1H); HRMS (FAB) m/z calcd for C28H35N4O6 [M+H]+: 523.6144,
found: 523.6139.
4.1.8.18. 4-{6-[2-(1-Boc-piperidin-4-yl)acetylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}butyric acid (16r). Mp = 191.5–192 C;
1H NMR d (500 MHz, d6-DMSO) 1.06–1.13 (m, 2H), 1.40 (s, 9H), 1.67
(d, J = 12.2 Hz, 2H), 1.84 (t, J = 7.2, 2H), 1.94–1.99 (m, 1H), 2.25–2.28
(m,4H), 2.67–2.79 (m,2H), 3.54 (t, J = 7.2 Hz, 2H), 3.93 (d, J = 10.1 Hz,
2H), 4.41 (s, 2H), 7.50 (d, J = 7.0 Hz, 1H), 7.68 (d, J = 7.0 Hz, 1H), 8.03
(s, 1H), 10.09 (s, 1H), 12.07 (s, 1H); HRMS (FAB) m/z calcd for
C24H34N3O6 [M+H]+: 460.5551, found: 459.5559.
4.1.8.19. 4-{6-[4-(1-Boc-piperidin-4-yl)butyrylamino]-1-oxo-1,3-
dihydroisoindol-2-yl}butyric acid (16s). Mp = 190–191 C;
1H NMR d (400 MHz, d6-DMSO) 0.94 (ddd, J = 24.4, 12.3, 3.9 Hz,
2H), 1.20–1.26 (m, 2H), 1.38 (s, 9H), 1.42–1.44 (m, 1H), 1.60–1.65
(m, 4H), 1.82 (dt, J = 14.2, 7.1 Hz, 2H), 2.24 (t, J = 7.2 Hz, 2H), 2.31
(t, J = 7.3 Hz, 2H), 2.63–2.72 (m, 2H), 3.51 (t, J = 7.0 Hz, 2H), 3.91
(d, J = 10.3 Hz, 2H), 4.40 (s, 2H), 7.49 (d, J = 8.3 Hz, 1H), 7.68 (dd,
J = 8.1, 1.5 Hz, 1H), 8.02 (s, 1H), 10.08 (s, 1H), 12.09 (br s, 1H);HRMS (FAB) m/z calcd for C26H37N3O6 [M+H]+: 488.6093, found:
488.6090.
4.1.8.20. 4-{6-[4-(1-Boc-piperidin-4-yl)benzoylamino]-1-oxo-
1,3-dihydroisoindol-2-yl}butyric acid (16t). Mp = 197–
197.5 C; 1H NMR d (400 MHz, d6-DMSO) 1.42 (s, 9H), 1.53 (ddd,
J = 25.1, 12.8, 3.9 Hz, 2H), 1.78 (d, J = 13.7 Hz, 2H), 1.84 (dt,
J = 14.2, 6.8 Hz, 2H), 2.25 (t, J = 7.2 Hz, 2H), 2.75–2.85 (m, 3H),
3.54 (t, J = 6.8 Hz, 2H), 4.09 (d, J = 9.8 Hz, 2H), 4.44 (s, 2H), 7.42
(d, J = 8.1 Hz, 2H), 7.55 (d, J = 8.3 Hz, 1H), 7.91–7.94 (m, 3H), 8.17
(s, 1H), 10.38 (s, 1H); HRMS (FAB) m/z calcd for C29H36N3O6
[M+H]+: 522.6268, found: 522.6261.
4.1.8.21. 4-{6-[(2-Boc-1,2,3,4-tetrahydroisoquinoline-7-carbonyl)-
amino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid
(16u). Mp = 90–93 C; 1H NMR d (400 MHz, d6-DMSO) 1.44
(s, 9H), 1.84 (dt, J = 13.9, 7.1 Hz, 2H), 2.26 (t, J = 7.0 Hz, 2H), 2.86
(t, J = 5.1 Hz, 2H), 3.54 (t, J = 6.7 Hz, 2H), 3.59 (t, J = 4.6 Hz, 2H),
4.45 (s, 2H), 4.60 (s, 2H), 7.33 (d, J = 7.6 Hz, 1H), 7.56 (d,
J = 8.1 Hz, 2H), 7.78–7.82 (m, 2H), 7.94 (d, J = 8.1 Hz, 1H), 8.18 (s,
1H), 10.37 (s, 1H), 12.14 (br s, 1H); HRMS (FAB) m/z calcd for
C27H32N3O6 [M+H]+: 494.5726, found: 494.5721.
4.1.9. General procedures for a preparation of compound 17
Method A. This method was used when the compound 16 was
not soluble in anhydrous CH2Cl2. The compound 16 (10 mmol)
was suspended in anhydrous CH2Cl2, and triﬂuoroacetic acid
(1 ml) was added. The precipitate was dissolved in a short time,
and the reaction solution was kept for 2 h, protected from mois-
ture. After the solvent was evaporated in vacuo to dryness, the res-
idue was dried in vacuo (2 mmHg) for 2 h at 40 C.
Method B. This method was used for the compound 16 soluble in
anhydrous CH2Cl2. The compound 16 (10 mmol) was dissolved in
anhydrous CH2Cl2, and the stream of dry HCl was passed through
the solution for 1 h. The solvent was evaporated, and the solid res-
idue was dried in vacuo (2 mm Hg) for 2 h at 40 C.
4.1.9.1. [1-Oxo-6-(2-piperidinium-4-yl-acetylamino)-1,3-dihyd-
roisoindol-2-yl]acetic acid triﬂuoroacetate (17a). Mp = 236–
239 C; 1H NMR d (500 MHz, d6-DMSO) 1.41 (ddd, J = 22.6, 10.6,
2.6 Hz, 2H), 1.85 (d, J = 13.8 Hz, 2H), 2.05–2.13 (m, 1H), 2.33 (d,
J = 6.7 Hz, 2H), 2.91 (dd, J = 22.8, 11.6 Hz, 2H), 3.27 (d, J = 11.9 Hz,
2H), 4.28 (s, 2H), 4.46 (s, 2H), 7.54 (d, J = 8.2 Hz, 1H), 7.69 (d,
J = 8.2 Hz, 1H), 8.10 (s, 1H), 8.37 (d, J = 8.7 Hz, 1H), 8.65 (d, J = 8.7 Hz,
1H), 10.23 (s, 1H); 13CNMR d (125 MHz, d6-DMSO) 28.64 (2C), 31.17
(1C), 43.05 (1C), 43.58 (2C), 43.95 (1C), 50.41 (1C), 113.61 (1C),
116.75 (1C, CF3CO

2 ), 123.10 (1C), 124.17 (s, 1C), 132.64 (1C), 137.06
(1C), 139.42 (1C), 158.81 (1C, CF3CO

2 ), 168.15 (1C), 170.37 (1C),
170.98 (1C); HRMS (FAB) m/z calcd for C17H22N3O4 [M+H]+:
332.3826, found: 332.3825.
4.1.9.2. [1-Oxo-6-(4-piperidinium-4-yl-butyrylamino)-1,3-dihyd-
roisoindol-2-yl]acetic acid triﬂuoroacetate (17b). Mp = 114–
115 C; 1H NMR d (400 MHz, d6-DMSO) 0.75–0.85 (m, 4H),
1.02–1.11 (m, 1H), 1.16 (dt, J = 14.9, 7.5 Hz, 2H), 1.35 (d,
J = 13.4 Hz, 2H), 1.88 (t, J = 7.2 Hz, 2H), 2.37 (dd, J = 32.5, 11.9 Hz,
1H), 2.80 (d, J = 12.2 Hz, 2H), 3.81 (s, 2H), 3.99 (s, 2H), 7.06 (d,
J = 8.3 Hz, 1H), 7.24 (dd, J = 8.2, 1.1 Hz, 1H), 7.64 (s, 1H), 7.86 (d,
J = 8.1 Hz, 1H), 8.17 (d, J = 8.1 Hz, 1H), 9.71 (s, 1H); HRMS (FAB)m/z
calcd for C19H26N3O4 [M+H]+: 360.4368, found: 360.4374.
4.1.9.3. [1-Oxo-6-(4-piperidinium-4-yl-benzoylamino)-1,3-dihy-
droisoindol-2-yl]acetic acid triﬂuoroacetate (17C). Mp
>300 C; 1H NMR d (400 MHz, d6-DMSO) 1.84 (ddd, J = 26.7, 12.5,
2.9 Hz, 2H), 1.99 (d, J = 13.2 Hz, 2H), 2.93–2.98 (m, 1H), 3.04 (dd,
J = 23.5, 12.2 Hz, 2H), 3.41 (d, J = 11.7 Hz, 2H), 4.30 (s, 2H), 4.50
4658 A. A. Krysko et al. / Bioorg. Med. Chem. 21 (2013) 4646–4661(s, 2H), 7.41 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.3 Hz, 1H), 7.95–7.99 (m,
3H), 8.23 (d, J = 1.5 Hz, 1H), 8.42 (dd, J = 21.3, 10.8 Hz, 1H), 8.69 (d,
J = 11.7 Hz, 1H), 10.44 (s, 1H); 13C NMR d (125 MHz, d6-DMSO)
29.67 (2C), 39.25 (1C), 43.98 (1C), 44.05 (2C), 50.46 (1C), 114.75
(1C), 116.89 (1C, CF3CO

2 ), 124.08 (1C), 124.22 (1C), 127.06 (2C),
128.58 (2C), 132.60 (1C), 133.56 (1C), 137.50 (1C), 139.58 (1C),
148.86 (1C), 158.77 (1C, CF3CO

2 ), 165.95 (1C), 168.18 (1C),
170.99 (1C); HRMS (FAB) m/z calcd for C22H24N3O4 [M+H]+:
394.4543, found: 394.4545.
4.1.9.4. [1-Oxo-6-(4-piperazinium-1-yl-benzoylamino)-1,3-dihyd-
roisoindol-2-yl]acetic acid triﬂuoroacetate (17d). Mp = 241–
242 C; 1H NMR d (500 MHz, d6-DMSO) 3.27 (s, 4H) 3.54 (s, 4H)
4.30 (s, 2H) 4.49 (s, 2H) 7.11 (d, J = 8.3 Hz, 2H) 7.58 (d, J = 8.1 Hz,
1H) 7.96–7.99 (m, 3H) 8.23 (s, 1H) 8.96 (s, 2H) 10.23 (s, 1H); 13C
NMR d (125 MHz, d6-DMSO) 42.98 (2C), 43.97 (1C), 44.90 (2C),
50.45 (1C), 114.70 (1C), 114.73 (2C), 116.67 (1C, CF3CO

2 ), 123.97
(1C), 124.19 (1C), 125.11 (1C), 129.70 (2C), 132.55 (1C), 137.15
(1C), 139.84 (1C), 152.63 (1C), 158.75 (1C, CF3CO

2 ), 165.47 (1C),
168.23 (1C), 171.01 (1C); HRMS (FAB) m/z calcd for C21H23N4O4
[M+H]+: 395.4419, found: 366.4422.
4.1.9.5. {1-Oxo-6-[(1,2,3,4-tetrahydroisoquinolinium-7-car-
bonyl)amino]-1,3-dihydroisoindol-2-yl}acetic acid chloride
(17e). Mp = 297.5–298 C (decomposes); 1H NMR d (400MHz,
d6-DMSO) 3.11 (t, J = 6.0 Hz, 2H), 3.40 (dd, J = 10.5, 6.3 Hz, 2H),
4.30 (s, 2H), 4.35 (t, J = 4.0 Hz, 2H), 4.50 (s, 2H), 7.40 (d, J = 8.3 Hz,
1H), 7.60 (d, J = 8.3 Hz, 1H), 7.90–7.92 (m, 2H), 8.01 (dd, J = 8.3,
1.7 Hz, 1H), 8.26 (d, J = 1.7 Hz, 1H), 9.76 (s, 2H), 10.59 (s, 1H); HRMS
(FAB) m/z calcd for C20H20N3O4 [M+H]+: 366.4001, found: 366.3997.
4.1.9.6. 3-[1-Oxo-6-(2-piperidinium-4-yl-acetylamino)-1,3-dihyd-
roisoindol-2-yl]propionic acid triﬂuoroacetate (17f). Mp = 112–
114 C; 1H NMR d (500 MHz, d6-DMSO) 1.40 (dd, J = 24.9, 13.2 Hz,
2H) 1.85 (d, J = 15.1 Hz, 2H) 2.03–2.14 (m, 1H), 2.33 (d, J = 7.0 Hz,
2H), 2.61 (t, J = 6.8 Hz, 2H), 2.91 (dd, J = 22.8, 11.5 Hz, 2H), 3.27 (d,
J = 11.9 Hz, 2H), 3.73 (t, J = 6.8 Hz, 2H), 4.44 (s, 2H), 7.51
(d, J = 8.0 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 8.05 (s, 1H), 8.30 (d,
J = 10.1 Hz, 1H), 8.59 (d, J = 7.0 Hz, 1H), 10.19 (s, 1H); 13C NMR d
(125 MHz, d6-DMSO) 28.65 (2C), 31.16 (1C), 33.36 (1C), 38.60 (1C),
43.04 (1C), 43.59 (2C), 49.97 (1C), 113.42 (1C), 116.58 (1C, CF3CO

2 ),
122.76 (1C), 124.02 (1C), 133.25 (1C), 136.85 (1C), 139.34 (1C),
158.74 (1C, CF3CO

2 ), 167.64 (1C), 170.31 (1C), 173.26 (1C); HRMS
(FAB) m/z calcd for C18H24N3O4 [M+H]+: 346.4097, found:
374.4690.
4.1.9.7. 3-[1-Oxo-6-(4-piperidinium-4-yl-butyrylamino)-1,3-dihyd-
roisoindol-2-yl]propionic acid triﬂuoroacetate (17g). Mp = 196–
197 C; 1H NMR d (400 MHz, d6-DMSO) 1.20–1.30 (m, 4H),
1.49–1.55 (m, 1H), 1.58–165 (m, 2H), 1.81 (d, J = 12.9 Hz, 2H),
2.34 (t, J = 6.6 Hz, 2H), 2.60 (t, J = 6.9 Hz, 2H), 2.83 (dd, J = 20.8,
10.0 Hz, 2H), 3.26 (d, J = 11.2 Hz, 2H), 3.72 (t, J = 6.9 Hz, 2H), 4.43
(s, 2H), 7.50 (d, J = 7.9 Hz, 1H), 7.67 (d, J = 7.5 Hz, 1H), 8.05 (s, 1H),
8.32 (s, 1H), 8.64 (s, 1H), 10.14 (s, 1H); HRMS (FAB) m/z calcd for
C20H28N3O4 [M+H]+: 374.4639, found: 374.4643.
4.1.9.8. 3-[1-Oxo-6-(4-piperidinium-4-yl-benzoylamino)-1,3-dihyd-
roisoindol-2-yl]propionic acid triﬂuoroacetate (17h). Mp = 243–
244 C (decomposes); 1H NMR d (400 MHz, d6-DMSO) 1.85 (dd,
J = 23.7, 11.5 Hz, 2H), 1.99 (d, J = 13.2 Hz, 2H), 2.63 (t, J = 7.0 Hz,
2H), 2.93–3.09 (m, 3H), 3.42 (d, J = 11.7 Hz, 2H), 3.75 (t, J = 7.0 Hz,
2H), 4.48 (s, 2H), 7.41 (d, J = 8.1 Hz, 2H), 7.57 (d, J = 8.3 Hz, 1H),
7.94 (dd, J = 8.3, 1.5 Hz, 1H), 7.97 (d, J = 8.1 Hz, 2H), 8.20 (d,
J = 1.5 Hz, 1H), 8.57 (s, 1H), 8.77 (t, J = 12.7, 2H), 10.43 (s, 1H);
HRMS (FAB) m/z calcd for C23H26N3O4 [M+H]+: 408.4814, found:
408.4816.4.1.9.9. 3-[1-Oxo-6-(4-piperazinium-1-yl-benzoylamino)-1,3-dihyd-
roisoindol-2-yl]propionic acid triﬂuoroacetate (17i). Mp = 212–
214 C; 1H NMR d (400 MHz, d6-DMSO + CCl4) 2.62 (t, J = 6.6 Hz,
2H), 3.27 (s, 4H), 3.53 (s, 4H), 3.74 (t, J = 6.6 Hz, 2H), 4.46 (s, 2H),
7.10 (d, J = 8.7 Hz, 2H), 7.55 (d, J = 8.3 Hz, 1H), 7.93–7.99 (m, 3H),
8.19 (s, 1H), 9.02 (s, 2H), 10.21 (s, 1H); 13C NMR d (125 MHz, d6-
DMSO) 33.39 (1C), 38.61 (1C), 42.98 (2C), 44.89 (2C), 50.01 (1C),
114.50 (1C), 114.72 (2C), 116.68 (1C, CF3CO

2 ), 123.83 (1C), 123.86
(1C), 129.69 (2C), 133.15 (1C), 136.94 (1C), 139.76 (1C), 152.61
(1C), 158.57 (1C, CF3CO

2 ), 165.44 (1C), 167.74 (1C), 173.29 (1C);
HRMS (FAB) m/z calcd for C22H25N4O4 [M+H]+: 409.4689, found:
409.4696.
4.1.9.10. 3-{1-Oxo-6-[(1,2,3,4-tetrahydroisoquinolinium-7-car-
bonyl)amino]-1,3-dihydroisoindol-2-yl}-propionic acid chlo-
ride (17j). Mp = 276–277.5 C; 1H NMR d (400MHz, d6-DMSO)
2.63 (t, J = 7.0 Hz, 2H), 3.10 (t, J = 5.9 Hz, 2H), 3.40 (dd, J = 6.5,
4.4 Hz, 2H), 3.74 (t, J = 7.0 Hz, 2H), 4.35 (s, 2H), 4.48 (s, 2H), 7.40 (d,
J = 8.6 Hz, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.89–7.92 (m, 2H), 7.97 (dd,
J = 8.3, 1.7 Hz, 1H), 8.21 (d, J = 1.2 Hz, 1H), 9.67 (s, 2H), 10.54 (s,
1H); HRMS (FAB) m/z calcd for C21H22N3O4 [M+H]+: 380.4272, found:
380.4281.
4.1.9.11. 3-[1-Oxo-6-(3-piperazinium-1-yl-benzoylamino)-1,3-di-
hydroisoindol-2-yl]propionic acid triﬂuoroacetate
(17k). Mp = 102–103 C; 1H NMR d (500 MHz, d6-DMSO) 2.63
(t, J = = 7.1 Hz, 2H), 3.29 (s, 4H), 3.46 (t, J = 4.8 Hz, 4H), 3.75 (t,
J = 6.8 Hz, 2H), 4.48 (s, 2H), 7.24 (d, J = 8.3 Hz, 1H), 7.43 (t,
J = 7.7 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.52 (s, 1H), 7.58 (d,
J = 8.1 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 8.17 (s, 1H), 8.88 (s, 2H),
10.39 (s, 1H); 13C NMR d (125 MHz, d6-DMSO) 33.39 (1C), 38.62
(1C), 43.17 (2C), 45.93 (2C), 50.04 (1C), 114.69 (1C), 115.37 (1C),
116.09 (1C, CF3CO

2 ), 119.66 (1C), 119.78 (1C), 123.93 (1C), 124.01
(1C), 129.72 (1C), 133.21 (1C), 136.18 (1C), 137.34 (1C), 139.44
(1C), 150.46 (1C), 158.76 (1C, CF3CO

2 ), 166.30 (1C), 167.67 (1C),
173.28 (1C); HRMS (FAB) m/z calcd for C22H25N4O4 [M+H]+:
409.4689, found: 409.4687.4.1.9.12. 3-[1-Oxo-6-(2-piperidinium-4-yl-acetylamino)-
1,3-dihydroisoindol-2-yl]butyric acid triﬂuoroacetate
(17l). Glassy substance; 1H NMR d (500MHz, d6-DMSO) 1.27 (d,
J = 6.7 Hz, 3H), 1.37–1.44 (m, 2H), 1.85 (d, J = 13.5 Hz, 2H), 2.05–
2.12 (m, 1H), 2.33 (d, J = 6.7 Hz, 2H), 2.62 (ddd, J = 30.8, 15.3,
7.4 Hz, 2H), 2.92 (dd, J = 22.8, 11.9 Hz, 2H), 3.27 (d, J = 11.9 Hz,
2H), 4.39 (dd, J = 27.8, 17.1 Hz, 2H), 4.59 (dt, J = 14.4, 7.5 Hz, 1H),
7.52 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 8.04 (s, 1H), 8.35
(d, J = 7.3 Hz, 1H), 8.62 (d, J = 7.0 Hz, 1H), 10.20 (s, 1H); HRMS
(FAB) m/z calcd for C19H26N3O4 [M+H]+: 360.4368, found:
360.4660.
4.1.9.13. 3-[1-Oxo-6-(4-piperidinium-4-yl-butyrylamino)-1,3-
dihydroisoindol-2-yl]butyric acid chloride (17m). Mp = 231–
234 C; 1H NMR d (500 MHz, d6-DMSO) 1.21–1.29 (m, 5H), 1.32
(dd, J = 23.1, 11.4 Hz, 2H), 1.49–1.56 (m, 1H), 1.61 (t, J = 6.6 Hz, 2H),
1.79 (d, J = 13.5 Hz, 2H), 2.36 (t, J = 5.8 Hz, 2H), 2.61 (ddd, J = 31.1,
15.1, 7.8 Hz, 2H), 2.80 (dd, J = 21.2, 10.5 Hz, 2H), 3.21 (d,
J = 11.2 Hz, 2H), 4.37 (dd, J = 26.7, 17.7 Hz, 2H), 4.59 (dd, J = 12.8,
6.4 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.74 (d, J = 7.0 Hz, 1H), 8.07 (s,
1H), 8.82 (d, J = 7.6 Hz, 1H), 9.09 (d, J = 7.6 Hz, 1H), 10.36 (s, 1H);
13C NMR d (125 MHz, d6-DMSO) 18.51 (1C), 22.02 (1C), 28.30 (2C),
32.86 (1C), 35.06 (1C), 36.33 (1C), 43.15 (2C), 44.43 (1C), 45.58
(1C), 112.87 (1C), 122.25 (1C), 123.48 (1C), 133.02 (1C), 136.05
(1C), 139.27 (1C), 166.82 (1C), 171.47 (1C), 172.25 (1C); HRMS
(FAB) m/z calcd for C21H30N3O4 [M+H]+: 388.4910, found:
388.4872.
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dihydroisoindol-2-yl]butyric acid chloride (17n). Mp = 200–
202 C; 1H NMR d (500 MHz, d6-DMSO) 1.28 (d, J = 6.7 Hz, 3H),
1.94–2.02 (m, 4H), 2.64 (ddd, J = 31.4, 15.2, 7.4 Hz, 2H), 2.94–3.04
(m, 3H), 3.36 (d, J = 10.6 Hz, 2H), 4.43 (dd, J = 27.8, 17.4 Hz, 2H),
4.61 (td, J = 14.0, 7.0 Hz, 1H), 7.40 (d, J = 7.8 Hz, 2H), 7.56 (d,
J = 8.0 Hz, 1H), 7.97–8.01 (m, 3H), 8.20 (s, 1H), 9.23–9.27 (m, 1H),
9.32–9.34 (m, J = 9.6 Hz, 1H), 10.50 (s, 1H); HRMS (FAB) m/z calcd
for C24H28N3O4 [M+H]+: 422.5085, found: 422.5091.4.1.9.15. 3-[1-Oxo-6-(4-piperazinium-4-yl-benzoylamino)-1,3-
dihydroisoindol-2-yl]butyric acid chloride (17o). Mp = 258–
258.5 C (decomposes); 1H NMR d (500 MHz, d6-DMSO) 1.28 (d,
J = 6.8 Hz, 3H), 2.64 (ddd, J = 31.2, 15.3, 7.1 Hz, 2H), 3.21 (s, 4H),
3.57 (t, J = 4.3, 4H), 4.41 (dd, J = 27.9, 17.6 Hz, 2H), 4.61 (td,
J = 13.6, 6.5 Hz, 1H), 7.10 (d, J = 8.3 Hz, 2H), 7.55 (d, J = 8.3 Hz,
2H), 7.97 (m, J = 8.1 Hz, 3H), 8.19 (s, 1H), 9.51 (s, 2H), 10.26 (s,
1H); 13C NMR d (125 MHz, d6-DMSO) 18.99 (1C), 42.74 (2C),
44.76 (2C), 44.88 (1C), 46.06 (1C), 114.53 (2C), 114.69 (1C),
123.83 (1C), 123.85 (1C), 125.03 (1C), 129.73 (2C), 133.42
(1C), 136.84 (1C), 139.80 (1C), 152.63 (1C), 165.45 (1C), 167.25
(1C), 172.71 (1C); HRMS (FAB) m/z calcd for C23H27N4O4 [M+H]+:
423.4960, found: 423.4953.4.1.9.16. 3-{1-Oxo-6-[(1,2,3,4-tetrahydroisoquinolinium-7-car-
bonyl)amino]-1,3-dihydroisoindol-2-yl}butyric acid chloride
(17p). Hygroscopic substance; 1H NMR d (500 MHz, d6-
DMSO) 1.29 (d, J = 6.6 Hz, 3H), 2.64 (ddd, J = 30.8, 15.2, 7.1 Hz,
2H), 3.09 (t, J = 6.0 Hz, 2H), 3.45 (d, J = 5.1 Hz, 2H), 4.39–4.48 (m,
4H), 4.62 (td, J = 14.2, 7.3 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.59 (d,
Jv8.6 Hz, 1H), 7.88–7.95 (m, 3H), 8.18 (s, 1H), 9.17 (s, 2H), 10.46
(s, 1H); HRMS (FAB) m/z calcd for C22H24N3O4 [M+H]+: 394.4543,
found: 394.4546.4.1.9.17. 3-[1-Oxo-6-(3-piperazinium-4-yl-benzoylamino)-1,3-
dihydroisoindol-2-yl]butyric acid chloride (17q). Mp = 232–
233 C; 1H NMR d (500 MHz, d6-DMSO) 1.28 (d, J = 5.4 Hz, 3H),
2.64 (ddd, J = 30.6, 14.8, 7.8 Hz, 2H), 3.24 (s, 4H), 3.52 (s, 4H),
4.42 (dd, J = 26.5, 17.4 Hz, 2H), 4.59–4.65 (m, 1H), 7.23 (d,
J = 7.5 Hz, 1H), 7.41 (t, J = 6.7 Hz, 1H), 7.50 (d, J = 6.5 Hz, 1H), 7.56
(d, J = 7.8 Hz, 1H), 7.60 (s, 1H), 7.99 (d, J = 7.3 Hz, 1H), 8.20 (s,
1H) 9.53 (s, 2H), 10.52 (s, 1H); 13C NMR d (125 MHz, d6-DMSO)
18.99 (1C), 38.72 (1C), 42.92 (2C), 44.90 (1C), 45.81 (2C), 46.10
(1C), 114.80 (1C), 115.49 (1C), 119.75 (1C), 123.91 (1C), 124.12
(1C), 129.69 (1C), 133.43 (1C), 136.08 (1C), 137.24 (1C), 139.49
(1C), 150.42 (1C), 166.28 (1C), 167.20 (1C), 172.70 (1C); HRMS
(FAB) m/z calcd for C23H27N4O4 [M+H]+: 423.4960, found:
423.4967.4.1.9.18. 4-[1-Oxo-6-(2-piperidinium-4-yl-acetylamino)-1,3-
dihydroisoindol-2-yl]butyric acid triﬂuoroacetate (17r).
Mp = 184–185 C; 1H NMR d (500 MHz, d6-DMSO) 1.37–1.45 (m,
2H), 1.80–1.87 (m, 4H), 2.05–2.12 (m, 1H), 2.25 (t, J = 6.9 Hz, 2H),
2.33 (d, J = 6.7 Hz, 2H), 2.91 (dd, J = 23.0, 11.2 Hz, 2H), 3.28 (d,
J = 11.2 Hz, 2H), 3.53 (t, J = 6.9 Hz, 2H), 4.41 (s, 2H), 7.51 (d,
J = 7.8 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 8.05 (s, 1H), 8.33–8.38 (m,
1H), 8.61–8.66 (m, 1H), 10.20 (s, 1H); 13C NMR d (125 MHz, d6-
DMSO) 23.72 (1C), 28.65 (2C), 31.17 (1C), 31.47 (1C), 41.66 (1C),
43.05 (1C), 43.58 (2C), 49.58 (1C), 113.49 (1C), 116.17 (1C,
CF3CO

2 ), 122.68 (1C), 124.02 (1C), 133.34 (1C), 136.83 (1C),
139.33 (1C), 158.56 (1C, CF3CO

2 ), 167.76 (1C), 170.31 (1C),
174.42 (1C); HRMS (FAB) m/z calcd for C19H26N3O4 [M+H]+:
360.4368, found: 360.4372.4.1.9.19. 4-[1-Oxo-6-(4-piperidinium-4-yl-butyrylamino)-1,3-
dihydroisoindol-2-yl]butyric acid triﬂuoroacetate
(17s). Mp = 200–202 C; 1H NMR d (400 MHz, d6-DMSO)
1.20–1.28 (m, 4H), 1.48–1.55 (m, 1H), 1.6 (dt, J = 15.0, 7.3 Hz,
2H), 1.78–1.86 (m, 4H), 2.24 (t, J = 7.2 Hz, 2H), 2.33 (t, J = 7.1 Hz,
2H), 2.83 (dd, J = 21.7, 10.9 Hz, 2H), 3.25 (d, J = 12.2 Hz, 2H), 3.51
(t, J = 6.8 Hz, 2H), 4.40 (s, 2H), 7.49 (d, J = 8.1 Hz, 1H), 7.66 (d,
J = 8.1 Hz, 1H), 8.04 (s, 1H), 8.27 (s, 1H), 8.68 (s, 1H), 10.13 (s,
1H); 13C NMR d (125 MHz, d6-DMSO) 22.41 (1C), 23.74 (1C),
28.87 (2C), 31.50 (1C), 33.30 (1C),35.49 (1C), 36.81 (1C), 41.69
(1C), 43.80 (2C), 49.59 (1C), 113.38 (1C), 116.44 (1C, CF3CO

2 ),
122.61 (1C), 123.96 (1C), 133.34 (1C), 136.61 (1C), 139.57 (1C),
157.75 (1C, CF3CO

2 ), 167.81 (1C), 171.78 (1C), 174.39 (1C); HRMS
(FAB) m/z calcd for C21H30N3O4 [M+H]+: 388.4910, found:
388.4904.4.1.9.20. 4-[1-Oxo-6-(4-piperidinium-4-yl-benzoylamino)-1,3-
dihydroisoindol-2-yl]butyric acid triﬂuoroacetate
(17t). Mp = 280–281 C; 1H NMR d (400 MHz, d6-DMSO)
1.79–1.90 (m, 4H), 2.00 (d, J = 12.7 Hz, 2H), 2.26 (t, J = 6.6 Hz,
2H), 2.93–3.08 (m, 3H), 3.40–3.43 (m, 2H), 3.54 (t, J = 6.5 Hz, 2H),
4.45 (s, 2H), 7.40 (d, J = 7.6 Hz, 2H), 7.56 (d, J = 7.6 Hz, 2H), 7.92–
7.97 (m, 3H), 8.18 (s, 1H), 8.52 (s, 1H), 8.77 (s, 1H), 10.43 (s, 1H);
13C NMR d (125 MHz, d6-DMSO) 23.76 (1C), 29.67 (2C), 31.53
(1C), 39.25 (1C), 41.72 (1C), 44.05 (2C), 49.66 (1C), 114.65 (1C),
116.72 (1C, CF3CO

2 ), 123.83 (1C), 123.93 (1C), 127.05 (2C),
128.57 (2C), 133.31 (1C), 133.58 (1C), 137.27 (1C), 139.48 (1C),
148.85 (1C), 158.77 (1C, CF3CCO

2 ), 165.91 (1C), 167.81 (1C),
174.41 (1C); HRMS (FAB) m/z calcd for C24H28N3O4 [M+H]+:
422.5085, found: 422.5088.4.1.9.21. 4-{1-Oxo-6-[(1,2,3,4-tetrahydroisoquinolinium-7-car-
bonyl)amino]-1,3-dihydroisoindol-2-yl}butyric acid chloride
(17u). Hygroscopic substance; 1H NMR d (400 MHz, d6-
DMSO) 1.86 (dt, J = 13.7, 6.7 Hz, 2H), 2.27 (t, J = 6.7 Hz, 2H), 3.09
(t, J = 5.2 Hz, 2H), 3.43–3.49 (m, 2H), 3.55 (t, J = 6.7 Hz, 2H), 4.40
(s, 2H), 4.46 (s, 2H), 7.42 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 8.3 Hz,
1H), 7.88 (s, 1H), 7.90–7.96 (m, 2H), 8.19 (s, 1H), 9.21 (s, 2H),
10.46 (s, 1H); HRMS (FAB) m/z calcd for C22H24N3O4 [M+H]+:
394.4543, found: 394.4540.4.2. X-ray diffraction
The X-ray data for 5b, 14, 17c–TfaOH5H2O, 17h-TfaOH2H2O,
and 17tH2O were collected utilizing MoKa radiation at Nonius
kappa CCD diffractometer at 100 K, and at Xcalibur Oxford Diffrac-
tion CCD diffractometer at room temperature for 17c, 17h, 17iH2O,
and 17jH2O. Final unit cell dimensions were obtained and reﬁned
on an entire data set. All calculations to solve the structures and to
reﬁne the models were carried out with the programs SHELXS97 and
SHELXL97.22 In all structures nonhydrogen nondisordered atoms have
been reﬁned with anisotropic displacement parameters. In 17c the
Tfa anion is disordered over two positions with the occupancies
0.876(3) and 0.124(4). The F atoms in the minor component were
reﬁned in isotropic approximation. In 17iH2O the ﬂuorine atoms
in the Tfa anion are disordered over three positions with the occu-
pancies 0.756(12), 0.156(10) and 0.088(7). The minor components
were reﬁned in isotropic approximation. The X-ray data for
17jH2O obtained from the poor-diffracting crystal revealed the
disordering of chloride anion and water molecule. For both of these
disordered species ﬁve close proximal positions with different
occupancies have been found and reﬁned in isotropic approxima-
tion with the combined occupancies of unity, both for Cl anion
and H2O. In all structures the C-bound H atoms were placed in cal-
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tion with Uiso(H) = 1.2 Ueq(C), the O- and N-bound H-atoms were
found from difference Fourier maps and reﬁned with isotropic dis-
placement parameters Uiso(H) = 1.5 Ueq(O), Uiso(H) = 1.2 Ueq(N). The
Figures were produced using Mercury.23 CCDC 912329–912337
contain the crystallographic data for studied compounds. These
data can be obtained free of charge from the Cambridge Crystallo-
graphic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.4.2.1. Crystal data and structure reﬁnement parameters for 5b
Empirical formula: C12H14N2O3 formula weight: 234.25. Crystal
system: monoclinic. Space group: P21/n. Unit cell dimensions:
a = 5.9940(3), b = 8.1340(5), c = 22.2920(13), b = 96.223(2),
V = 1080.45(11) Å3. Index ranges: 7 6 h 6 7, 10 6 k 6 9,
23 6 l 6 28. Range for data collection from 1.84 to 26.99, Z = 4.
Dcalc = 1.440 mg/m3. F(000) = 496. Reﬂections collected 6247. Inde-
pendent reﬂections 2360 [R(int) = 0.0429]. Data/restraints/parame-
ters2360:0:163.Reﬁnementmethod:Fullmatrix least squaresonF2.
Goodness-of-ﬁt on F2: 1.006. Final R indices [I > 2(I)]: R1 = 0.0493,
wR2 = 0.1350. R indices (all data): R1 = 0.0666,wR2 = 0.1464. Largest
diff. peak and hole: 0.285 and 0.286 e Å3.4.2.2. Crystal data and structure reﬁnement parameters for 14
Empirical formula: C15H19NO4 formula weight: 277.31. Crystal
system: monoclinic. Space group: P21/c. Unit cell dimensions:
a = 11.9373(9), b = 10.3546(8), c = 11.5307(9), b = 102.543(4),
V = 1391.25(19) Å3. Index ranges: 15 6 h 6 15, 12 6 k 6 13,
14 6 l 6 14. Range for data collection from 2.63 to 27.00, Z = 4.
Dcalc = 1.324 mg/m3. F(000) = 592. Reﬂections collected 5573. Inde-
pendent reﬂections 3015 [R(int) = 0.0541]. Data/restraints/parame-
ters3015:0:188.Reﬁnementmethod:Fullmatrix least squaresonF2.
Goodness-of-ﬁt on F2: 1.006. Final R indices [I > 2(I)]: R1 = 0.0633,
wR2 = 0.1400. R indices (all data): R1 = 0.0910,wR2 = 0.1546. Largest
diff. peak and hole: 0.248 and 0.309 e Å3.4.2.3. Crystal data and structure reﬁnement parameters for
[1-oxo-6-(4-piperidinium-4-yl-benzoylamino)-1,3-dihydrois-
oindol-2-yl]acetate pentahydrate (17c-TfaOH5H2O)
Empirical formula: C22H33N3O9 formula weight: 483.51. Crystal
system: monoclinic. Space group: P21/n. Unit cell dimensions:
a = 12.8160(3), b = 11.1350(3), c = 17.1290(5) Å, b = 108.7240(8),
V = 2315.04(11) Å3. Index ranges: 16 6 h 6 16, 13 6 k 6 13,
21 6 l 6 21. Range for data collection from 2.40 to 26.50, Z = 4.
Dcalc = 1.387 mg/m3. F(000) = 1032. Reﬂections collected 18213.
Independent reﬂections 4793 [R(int) = 0.0500]. Data/restraints/
parameters 4793:0:346. Reﬁnement method: Full matrix least
squares on F2. Goodness-of-ﬁt on F2: 1.003. Final R indices [I > 2(I)]:
R1 = 0.0474, wR2 = 0.1117. R indices (all data): R1 = 0.0596,
wR2 = 0.1185. Largest diff. peak and hole: 0.364 and0.366 e Å3.4.2.4. Crystal data and structure reﬁnement parameters for 17c
Empirical formula: C24H24F3N3O6 formula weight: 507.46. Crys-
tal system: triclinic. Space group: P-1. Unit cell dimensions:
a = 7.2240(8), b = 9.8920(9), c = 17.329(2), a = 97.142(7),
b = 93.852(4), c = 97.901(7), V = 1212.6(2) Å3. Index ranges:
8 6 h 6 8, 11 6 k 6 8, 20 6 l 6 20. Range for data collection
from 2.10 to 25.00, Z = 2. Dcalc = 1.390 mg/m3. F(000) = 528.
Reﬂections collected 6908. Independent reﬂections 4135
[R(int) = 0.0374]. Data/restraints/parameters 4135:16:360. Reﬁne-
ment method: Full matrix least squares on F2. Goodness-of-ﬁt on
F2: 1.001. Final R indices [I > 2(I)]: R1 = 0.0781,wR2 = 0.1818. R indi-
ces (all data): R1 = 0.0972, wR2 = 0.1918. Largest diff. peak and
hole: 0.639 and 0.459 e Å3.4.2.5. Crystal data and structure reﬁnement parameters for 17h
Empirical formula: C25H26F3N3O6 formula weight: 521.49. Crys-
tal system: monoclinic. Space group: P21/c. Unit cell dimensions:
a = 13.675(4), b = 6.202(8), c = 30.779(17) Å, b = 115.42(3),
V = 2358(3) Å3. Index ranges: 14 6 h 6 14, 6 6 k 6 6,
32 6 l 6 31. Range for data collection from 1.65 to 22.06,
Z = 4. Dcalc = 1.469 mg/m3. F(000) = 1088. Reﬂections collected
4516. Independent reﬂections 2242 [R(int) = 0.1700]. Data/re-
straints/parameters 2242:228:316. Reﬁnement method: Full ma-
trix least squares on F2. Goodness-of-ﬁt on F2: 1.133. Final R
indices [I > 2(I)]: R1 = 0.2046, wR2 = 0.3531. R indices (all data):
R1 = 0.2967, wR2 = 0.3908. Largest diff. peak and hole: 0.516 and
0.414 e Å3.4.2.6. Crystal data and structure reﬁnement parameters for
3-[1-oxo-6-(4-piperidinium-4-yl-benzoylamino)-1,3-
dihydroisoindol-2-yl]propionate dihydrate (17h-TfaOH2H2O)
Empirical formula: C23H29N3O6 formula weight: 443.49. Crystal
system: triclinic. Space group: P-1. Unit cell dimensions:
a = 7.8610(4), b = 10.0294(4), c = 15.0560(5) Å, a = 96.388(2),
b = 99.306(2), c = 111.4031(18), V = 1071.73(8) Å3. Index ranges:
9 6 h 6 9, 12 6 k 6 12, 18 6 l 6 18. Range for data collection
from 2.22 to 25.49, Z = 2. Dcalc = 1.374 mg/m3. F(000) = 472.
Reﬂections collected 7408. Independent reﬂections 3961
[R(int) = 0.0525]. Data/restraints/parameters 3961:0:310. Reﬁne-
ment method: Full matrix least squares on F2. Goodness-of-ﬁt on
F2: 1.007. Final R indices [I > 2(I)]: R1 = 0.0696,wR2 = 0.1778. R indi-
ces (all data): R1 = 0.0923, wR2 = 0.1913. Largest diff. peak and
hole: 0.400 and 0.284 e Å3.4.2.7. Crystal data and structure reﬁnement parameters for
3-[1-oxo-6-(4-piperazinium-1-yl-benzoylamino)-1,3-
dihydroisoindol-2-yl]propionic acid triﬂuoroacetate hydrate
(17iH2O)
Empirical formula: C24H27F3N4O7 formula weight: 540.50. Crys-
tal system: triclinic. Space group: P-1. Unit cell dimensions:
a = 8.9199(5), b = 11.8606(9), c = 12.0078(7) Å, a = 92.329(5),
b = 93.603(5), c = 106.407(6), V = 1213.97(13) Å3. Index ranges:
6 6 h 6 10, 14 6 k 6 13, 14 6 l 6 14. Range for data collection
from 3.02 to 25.05, Z = 2. Dcalc = 1.479 mg/m3. F(000) = 564.
Reﬂections collected 7655. Independent reﬂections 4295
[R(int) = 0.0251]. Data/restraints/parameters 4295:109:383.
Reﬁnement method: Full matrix least squares on F2. Goodness-
of-ﬁt on F2: 1.004. Final R indices [I > 2(I)]: R1 = 0.0507,
wR2 = 0.1147. R indices (all data): R1 = 0.0923, wR2 = 0.1241. Larg-
est diff. peak and hole: 0.495 and 0.278 e Å3.4.2.8. Crystal data and structure reﬁnement parameters for 3-
{1-oxo-6-[(1,2,3,4-tetrahydroisoquinolinium-7-
carbonyl)amino]-1,3-dihydroisoindol-2-yl}propionic acid
chloride hydrate (17jH2O)
Empirical formula: C21H22ClN3O5 formula weight: 431.87. Crys-
tal system: monoclinic. Space group: C2/c. Unit cell dimensions:
a = 46.068(7), b = 5.0936(7), c = 18.848(3) Å, b = 109.607(13),
V = 4166.3(11) Å3. Index ranges: 54 6 h 6 54, 6 6 k 6 5,
22 6 l 6 18. Range for data collection from 2.98 to 25.05,
Z = 8. Dcalc = 1.377 mg/m3. F(000) = 1808. Reﬂections collected
6442. Independent reﬂections 3648 [R(int) = 0.0647]. Data/re-
straints/parameters 3648:2:290. Reﬁnement method: Full matrix
least squares on F2. Goodness-of-ﬁt on F2: 1.004. Final R indices
[I > 2(I)]: R1 = 0.0500, wR2 = 0.0917. R indices (all data):
R1 = 0.2115, wR2 = 0.1289. Largest diff. peak and hole: 0.209 and
0.279 e Å3.
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4-[1-oxo-6-(4-piperidinium-4-yl-benzoylamino)-1,3-
dihydroisoindol-2-yl]butyric acid triﬂuoroacetate hydrate
(17tH2O)
Empirical formula: C26H30F3N3O7 formula weight: 553.53. Crys-
tal system: triclinic. Space group: P-1. Unit cell dimensions:
a = 7.1440(6), b = 9.3970(6), c = 20.6680(16) Å, a = 84.549(5),
b = 88.466(5), c = 69.296(5), V = 1291.98(17) Å3. Index ranges:
7 6 h 6 7, 10 6 k 6 10, 22 6 l 6 22. Range for data collection
from 1.98 to 22.50, Z = 2. Dcalc = 1.423 mg/m3. F(000) = 580.
Reﬂections collected 5446. Independent reﬂections 3288 [R(int)
= 0.0838]. Data/restraints/parameters 3288:1:362. Reﬁnement
method: Full matrix least squares on F2. Goodness-of-ﬁt on F2:
1.011. Final R indices [I > 2(I)]: R1 = 0.0887, wR2 = 0.1985. R indices
(all data): R1 = 0.1432, wR2 = 0.2232. Largest diff. peak and hole:
0.345 and 0.342 e Å3.
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